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Abstract Venous thromboembolism (VTE), which may
manifest as pulmonary embolism (PE) or deep vein
thrombosis (DVT), is a serious and potentially fatal con-
dition. Treatment and prevention of obstetric-related VTE
is complicated by the need to consider fetal, as well as
maternal, wellbeing when making management decisions.
Although absolute VTE rates in this population are low,
obstetric-associated VTE is an important cause of maternal
morbidity and mortality. This manuscript, initiated by the
Anticoagulation Forum, provides practical clinical guid-
ance on the prevention and treatment of obstetric-associ-
ated VTE based on existing guidelines and consensus
expert opinion based on available literature where guide-
lines are lacking.
Keywords Pregnancy  Obstetric  Venous
thromboembolism  Pulmonary embolism  Deep vein
thrombosis  Prophylaxis  Anticoagulants
Introduction
Venous thromboembolism (VTE), which may manifest as
pulmonary embolism (PE) or deep vein thrombosis (DVT),
complicates 0.5–2.2 per 1000 deliveries, depending on the
population studied [1–8]. During pregnancy, the risk of
VTE is increased five to tenfold compared to non-pregnant
women of comparable age [1, 9, 10]. The postpartum
period poses a higher risk [1, 7, 10] and during this time
frame, the daily risk of VTE is increased 15- to 35-fold
compared to age-matched non-pregnant women [1, 9]. The
daily risk of pregnancy-associated VTE appears greatest
during the first 3–6 weeks postpartum [1, 7]. After that, the
risk declines rapidly, although a small residual risk increase
may persist for 12 weeks after delivery [7, 10, 11].
Although the absolute VTE rates are low, pregnancy-as-
sociated VTE is an important cause of maternal morbidity
[12–14] and mortality [15, 16].
The treatment and prevention of pregnancy-associated
VTE is challenging because of the potential for both fetal
and maternal complications, as well as the paucity of rel-
evant high quality research. Although evidence-based
guideline recommendations for the use of anticoagulants in
this patient population have been published [17–25], they
are based largely upon observational studies and extrapo-
lated from data in non-pregnant patients. The lack of high
quality data specific to pregnancy results in a lack of
consistency in their recommendations. This chapter re-
views the published evidence base and uses that informa-
tion, as well as published guidelines, to provide practical
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guidance for the management and prevention of VTE
during pregnancy.
Methods
The goal of this chapter is to provide guidance to providers
on how best to individualize care to patients with preg-
nancy-associated VTE, with specific focus on the questions
listed in Table 1. Questions were developed by consensus
from the authors. To address these questions, current
guidelines from the American College of Obstetricians and
Gynecologists (ACOG) [17, 18], the Society of Obstetri-
cians and Gynaecologists of Canada (SOGC) [19], the
Royal College of Obstetricians and Gynaecologists
(RCOG) [20, 21], clinicians from Australia and New
Zealand [22], and American College of Chest Physicians
(ACCP) [23–25] were reviewed and relevant recommen-
dations were extracted (Tables 2A–2D). The literature was
reviewed and data from relevant systematic reviews, ran-
domized trials, and observational studies were incorpo-
rated. The authors’ consensus interpretation of these
studies, in the context of the realities of VTE care, was
distilled into the practical recommendations that are pre-
sented in this article.
In making recommendations regarding the need for
prophylaxis, the panel used a risk threshold of 3 % and
greater for antepartum prophylaxis and 3 % and greater for
postpartum prophylaxis. For risk factors for which only
case control data are available, a relative risk of at least
30-fold antepartum and 60-fold postpartum are required to
reach our thresholds, assuming antepartum and postpartum
baseline risks of 0.1 and 0.05 %, respectively [26]. The
prophylaxis thresholds above were determined by the
majority result of an anonymous vote of the authors. It is
important to note that there was inconsistency between the
authors in their risk threshold for recommending prophy-
laxis. For antepartum prophylaxis, three chose 3 % or
greater, one 5 % or greater, and one 1 % or greater. For
postpartum prophylaxis, four selected a threshold of 3 % or
greater and one chose 1 % or greater. The variability in risk
thresholds is not surprising given the limitations of the
available evidence, as well as the competing benefits and
drawbacks of prophylaxis. The panel would emphasize that
changes in the antepartum threshold to 5 or 1 % and to the
postpartum threshold to 1 % would markedly change the
recommendations that follow. When making recommen-
dations, the panel also took into account the estimated risks
of major bleeding with prophylactic LMWH (antepartum:
0; 95 % CI 0–0.6 % and postpartum: 0.3 %; 95 % CI
0–1.0 %) [26]; the variability in risk estimates reported in
the literature, the 95 % confidence intervals around the risk
estimates, and the strengths or weaknesses of relevant
study methodology in addition to the above threshold
limits.
Guidance
1. What are the risks of anticoagulant use during
pregnancy?
During pregnancy, the risks posed to the fetus by anti-
coagulant therapy, as well as maternal efficacy and safety
must be considered. Vitamin K antagonists cross the pla-
centa and have the potential to cause teratogenicity as well
as pregnancy loss, fetal bleeding, and neurodevelopmental
deficits [27–34]. Discontinuation of vitamin K antagonists
prior to the 6th week of gestation essentially eliminates the
risk of warfarin embryopathy [29, 30, 32]. Pregnant women
were excluded from participating in clinical trials evalu-
ating the oral direct thrombin and factor Xa inhibitors (e.g.
dabigatran, rivaroxaban, apixaban, edoxaban). These
agents are likely to cross the placenta and their human
reproductive risks are unknown [35–38]. Fondaparinux
appears to cross the placenta in small quantities [39].
Reports of the successful use of fondaparinux in pregnant
woman have been published [39–46] but it is important to
recognize that many of these involve second trimester or
later exposure.
Unfractionated heparin (UFH), low molecular weight
heparin (LMWH) and danaparoid (a heparinoid) do not
cross the placenta and are safe for the fetus [47–55].
Although UFH can be used during pregnancy for both
prevention and treatment of thromboembolism, LMWH
has a better safety profile than UFH [56, 57] and the
incidence of bleeding and other complications (e.g. heparin
induced thrombocytopenia [HIT], and heparin-associated
osteoporosis) are lower in pregnant women receiving
LMWH than with UFH [58–69]. LMWHs are eliminated
primarily by renal excretion and may accumulate in
patients with significant renal dysfunction. In the non-
pregnant population, it has been suggested that therapeutic
dose LMWH not be used in patients with significant renal
impairment (e.g. a glomerular filtration rate (GFR) of less
than 30 mL/min), although it is recognized that accumu-
lation in patients with renal impairment may differ between
the various LMWHs [70].
Table 1 Guidance questions to be considered
1. What are the risks of anticoagulant use during pregnancy?
2. What are the risks of anticoagulation in breastfeeding women?
3. How is venous thromboembolism during pregnancy treated?
4. How is pregnancy-associated VTE prevented?
5. How is peripartum anticoagulation managed?
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Table 2A Guideline summary—anticoagulant choice
American College
of Obstetricians
and Gynecologists
(ACOG) [17, 18]
Society of Obstetricians and
Gynaecologists of Canada
(SOGC) [19]
Royal College of
Obstetricians and
Gynaecologists (RCOG) [20,
21]
Australia/New Zealand
[22]
American College of Chest
Physicians (ACCP) [23]
During pregnancy
Heparin
compounds are
the preferred
anticoagulant
during
pregnancy
(Level B)
LMWH is the preferred
pharmacologic agent over
UFH for treatment of
VTE during pregnancy
(II-2A)
LMWH is the preferred
pharmacologic agent over
UFH for antepartum
thromboprophylaxis (III-
A)
LMWH is the preferred
pharmacologic agent over
UFH for postpartum
thromboprophylaxis
(IIIA)
Vitamin K antagonists
should only be considered
for treatment of VTE in
exceptional circumstances
(II-2A)
Recommend against the use
of oral Xa inhibitors and
oral direct thrombin
inhibitors (III-D)
LMWH is the preferred
anticoagulant for treatment
of acute VTE during
pregnancy (B)
LMWHs are the agents of
choice for antenatal and
postnatal
thromboprophylaxis (A)
Because of their adverse
effects on the fetus, vitamin
K antagonists should not be
used for antenatal VTE
treatment (C)
Women receiving long-term
vitamin K antagonist
therapy should be
counselled about the risks of
vitamin K antagonists to the
fetus and advised to stop
these medications and
change to LMWH as soon as
pregnancy is confirmed
(ideally within 2 weeks of
the missed period and before
the 6th week of pregnancy)
(no grade)
Oral thrombin and Xa
inhibitors should be avoided
in pregnant women (no
grade)
Women with VTE in
pregnancy should not be
treated with vitamin K
antagonists, such as
warfarin (Consensus
Level 1)
For pregnant patients,
recommend LMWH for
prevention and treatment of
VTE, instead of UFH
(Grade 1B)
For pregnant women,
recommend avoiding the use
of oral direct thrombin and
factor Xa inhibitors (Grade
1C)
For women requiring long-
term vitamin K antagonists
who are attempting
pregnancy and are
candidates for LMWH
substitution, suggest
performing frequent
pregnancy tests and
substituting LMWH for
vitamin K antagonists when
pregnancy is achieved rather
than switching to LMWH
while attempting pregnancy
(Grade 2C) [Remark:
Women who place little
value on avoiding the risks,
inconvenience, and costs of
LMWH therapy of uncertain
duration while awaiting
pregnancy and a high value
on minimizing the risks of
early miscarriage associated
with vitamin K antagonist
therapy are likely to choose
LMWH while attempting
pregnancy]
During pregnancy if HIT or other heparin allergy
Fondaparinux is
preferred if
there is severe
cutaneous
heparin allergy
or HIT (no
grade)
Consultation with a
hematologist or
thrombosis specialist is
recommended to consider
the use of heparinoids if
HIT occurs (II-3B)
Pregnant women who develop
HIT or have heparin allergy
and require continuing
anticoagulant therapy
should be managed an
alternative anticoagulant
under specialist advice (C)
Consideration should be
given to the use of
fondaparinux, argatroban, or
r-hirudin in pregnant women
who are unable to tolerate
heparin, UFH or danaparoid
and who require continuing
anticoagulant therapy (D)
For pregnant women, suggest
limiting the use of
fondaparinux and parenteral
direct thrombin inhibitors to
those with severe allergic
reactions to heparin (e.g.
HIT) who cannot receive
danaparoid (Grade 1C)
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As outlined in Table 2A, there is clear consensus
amongst the reviewed guideline documents that, in general,
LMWH is the preferred anticoagulant for the management
and treatment of VTE in pregnancy [17–25].
Guidance Statement
• Physicians should counsel women receiving long-term
therapy with vitamin K antagonists and the oral direct-
acting anticoagulants about the fetal risks of these
medications before pregnancy occurs.
• LMWH is the drug of choice for treatment and
prevention of VTE in pregnancy, except in patients
with HIT, a history of HIT, or significant renal
dysfunction. UFH is preferred in patients with signif-
icant renal dysfunction.
• For women taking vitamin K antagonists, two options
are available to reduce the risk of warfarin embryopa-
thy. The first is to advise women to perform frequent
pregnancy tests and substitute LMWH for warfarin
once pregnancy is achieved and before 6 weeks gesta-
tion. Alternatively, LMWH or UFH can be substituted
for vitamin K antagonists before conception is
attempted. Although the latter approach minimizes the
risks of early miscarriage associated with vitamin K
antagonist therapy, it lengthens the duration of expo-
sure to LMWH or UFH and, therefore, is costly and
exposes the patient to a greater burden of treatment
associated with the use of injectable heparin therapy.
Since warfarin embryopathy is unlikely to result from
warfarin exposure before 6 weeks, the first option is
usually favored by guidelines. Although the manage-
ment of women who are receiving long-term therapy
with oral direct thrombin and factor Xa inhibitors and
attempting to conceive remains controversial, it has
been suggested that these women should be converted
to a coumarin or LMWH before conception is
Table 2A continued
American College
of Obstetricians
and Gynecologists
(ACOG) [17, 18]
Society of Obstetricians and
Gynaecologists of Canada
(SOGC) [19]
Royal College of
Obstetricians and
Gynaecologists (RCOG) [20,
21]
Australia/New Zealand
[22]
American College of Chest
Physicians (ACCP) [23]
During breastfeeding
Warfarin,
LMWH,
unfractionated
heparin are
compatible
with breast
feeding (Level
B)
Women should be advised
that neither UFH, LMWH
nor warfarin is
contraindicated in
breastfeeding (D)
For lactating women using
warfarin, acenocoumarol or
UFH who wish to
breastfeed, recommend
continuing the use of
warfarin, acenocoumarol, or
UFH (Grade 1A)
For lactating women using
LMWH, danaparoid, or
r-hirudin who wish to
breastfeed, recommend
continuing the use of
LMWH, danaparoid, or
r-hirudin (Grade 1B)
For breastfeeding women,
suggest alternative
anticoagulants rather than
fondaparinux (Grade 2C)
For breastfeeding women, we
recommend alternative
anticoagulants rather than
oral direct thrombin and
factor Xa inhibitors (Grade
1C)
For lactating women using
low-dose Aspirin for
vascular indications who
wish to breastfeed, we
suggest continuing this
medication (Grade 1B)
Please see individual references for grading criteria
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Table 2B Guideline summary—management of acute venous thromboembolism
American College of
Obstetricians and
Gynecologists (ACOG)
[17, 18]
Society of Obstetricians
and Gynaecologists of
Canada (SOGC) [19]
Royal College of
Obstetricians and
Gynaecologists (RCOG)
[20, 21]
Australia/New Zealand
[22]
American College of
Chest Physicians (ACCP)
[23]
Hospitalization
Hospitalization in cases
of hemodynamic
instability, large VTE
or maternal co-
morbidity (no grade)
Pregnant women with
acute VTE should be
hospitalized or followed
closely as outpatients for
the first 2 weeks after
diagnosis (III-C)
Inpatient observation and
treatment of pregnant
women with PE for the
first few days following
diagnosis is
recommended
(Consensus Level 1)
Anticoagulation
Therapeutic
anticoagulation during
current pregnancy
(Level C)
Manufacturer’s
recommendations for
LMWH dosing based on
patient’s current weight
should be adhered to (II-
1A)
LMWH can be
administered once or
twice a day depending on
the agent selected (III-
C)
Following initial
treatment, anticoagulant
intensity can be
decreased to
intermediate or
prophylactic dose for the
remainder of the
pregnancy and for at
least 6 weeks postpartum
(III-C)
LMWH be given daily in
the women’s booking
early pregnancy weight,
There is insufficient
evidence to recommend
whether the dose of
LMWH should be given
once daily or in two
divided doses (C)
Treatment of acute VTE in
pregnancy should be
with LMWH given once-
daily or twice-daily at
therapeutic doses. There
is currently insufficient
evidence to favour one
dose regimen over the
other (Group Consensus
Level 1)
Women with PE or more
extensive DVT (i.e.
iliofemoral thrombosis
during pregnancy should
receive twice-daily
LMWH for at least
8–12 weeks, after which
time a reduction to a
once-daily regimen may
be considered
(Consensus Level 2)
For pregnant women with
acute VTE, recommend
therapy with weight
adjusted-dose
subcutaneous LMWH
over adjusted-dose UFH
(Grade 1B)
A decrease in dosing
intensity later in therapy
to 75 % of a full-
treatment dose may be
useful in women at risk
of anticoagulant-related
bleeding or heparin-
associated osteoporosis
(no grade)
Intravenous UFH can be
considered in the initial
treatment of PE and
in situations in which
delivery, surgery, or
thrombolysis may be
necessary (no grade)
Intravenous UFH is the
preferred treatment in
massive PE with
cardiovascular collapse
(B)
Consideration should be
given to the use of
intravenous UFH when
VTE occurs at term (D)
When intravenous UFH is
preferred (e.g. renal
dysfunction), it can be
used either with initial
intravenous therapy
followed by adjusted-
dose subcutaneous UFH
given every 12 h or q
12 h adjusted
subcutaneous UFH
alone. With
subcutaneous therapy,
UFH doses should be
adjusted to prolong a
midinterval (6 h post-
injection) activated
partial thromboplastin
time into the therapeutic
range (no grade)
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Table 2B continued
American College of
Obstetricians and
Gynecologists (ACOG) [17,
18]
Society of
Obstetricians and
Gynaecologists of
Canada (SOGC) [19]
Royal College of Obstetricians
and Gynaecologists (RCOG)
[20, 21]
Australia/New Zealand [22] American
College of Chest
Physicians
(ACCP) [23]
Managing of life threatening PE
Intravenous UFH can be
considered in the initial
treatment of PE and
in situations in which
thrombolysis may be
necessary (no grade)
Thrombolytic therapy
should only be
considered in limb-
threatening DVT or
massive PE (III-C)
Collapsed shocked patients
should be assessed by a team
of experienced clinicians,
including the on-call
consultant obstetrician, who
should decide on an individual
basis whether a woman
receives intravenous UFH,
thrombolytic therapy or
thoracotomy and surgical
embolectomy. Management
should involve a
multidisciplinary team
including senior physicians,
obstetricians and radiologists
(no grade)
Intravenous UFH is the
preferred, initial treatment in
massive PE with
cardiovascular compromise
(B)
The on-call medical team
should be contacted
immediately. An urgent
portable echocardiogram or
CT pulmonary angiogram
within 1 h of presentation
should be arranged. If massive
PE is confirmed or, in extreme
circumstances prior to
confirmation, immediate
thrombolysis should be
considered (no grade)
Thrombolysis should only be
considered in pregnancy for
women with life or limb-
threatening complications of
acute VTE (Consensus Level
I)
Thrombolytic
therapy is best
reserved for
life-
threatening
VTE (no
grade)
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Table 2B continued
American
College of
Obstetricians
and
Gynecologists
(ACOG) [17,
18]
Society of Obstetricians and
Gynaecologists of Canada
(SOGC) [19]
Royal College of
Obstetricians and
Gynaecologists (RCOG) [20,
21]
Australia/New Zealand [22] American College of Chest
Physicians (ACCP) [23]
Graded compression stockings
Use of graded compression
stockings can be
considered for symptom
relief in pregnant women
with acute proximal DVT
(III-C)
In the initial management of
DVT, the leg should be
elevated and a graduated
elastic compression
stocking applied to reduce
edema. Mobilization with
graduated compression
stockings should be
encouraged (B)
Following a DVT, graduated
compression stockings
should be worn on the
affected leg to reduce pain
and swelling. Clinicians
should be aware that the
role of compression
stockings in the prevention
of post-thrombotic
syndrome is unclear (B)
All women with confirmed
DVT should wear a below-
knee class 2 (30-40 mmHg)
compression stocking for
two years (Consensus
Level I)
In patients with acute
symptomatic DVT of the
leg, suggest the use of
compression stockings
(Grade 2B) [24]
Treatment duration
Following acute VTE,
therapeutic anticoagulation
is recommended for a
minimum of 3 months (I-
A)
Treatment with therapeutic
doses of subcutaneous
LMWH should be
employed during the
remainder of the pregnancy
(B)
Therapeutic anticoagulant
therapy should be continued
for the duration of the
pregnancy and for at least
6 weeks postnatally and
until at least 3 months of
treatment has been given in
total. Before discontinuing
treatment, the continuing
risk of thrombosis should be
assessed (C)
Anticoagulant therapy in
pregnant women with acute
proximal DVT and/or PE
should be continued until at
least 6 weeks postpartum or
longer, if necessary, to
complete a minimum total
treatment period of
6 months (Consensus
Level I)
A shorter total duration of
therapy (6–8 weeks) may
be appropriate in women
with isolated distal DVT,
with consideration given to
prophylactic dose LMWH
for the remainder of the
pregnancy (Consensus
Level I)
For pregnant women with
acute VTE suggest that
anticoagulants should be
continued for at least
6 weeks postpartum for a
minimum duration of
therapy of 3 months) in
comparison with shorter
durations of treatment
(Grade 2C)
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Table 2B continued
American College of
Obstetricians and
Gynecologists (ACOG)
[17, 18]
Society of Obstetricians
and Gynaecologists of
Canada (SOGC) [19]
Royal College of
Obstetricians and
Gynaecologists (RCOG)
[20, 21]
Australia/New Zealand [22] American College of Chest
Physicians (ACCP) [23]
Insertion of IVC filter
Women with
recurrent VTE
despite therapeutic
anticoagulation may
be candidates for
IVC filter placement
(no grade)
IVC filters should only be
used in pregnant women
with acute PE or DVT
and contraindications to
anticoagulation (III-C)
Consideration should be
given to the use of a
temporary IVC filter in
women with proven DVT
who have recurrent PE
despite adequate
anticoagulation and in
the peripartum period for
patients with iliac vein
DVT to reduce the risk of
PE (D)
Insertion of a temporary
IVC filter should only be
considered in pregnant
patients with recent acute
venous thrombosis in
whom therapeutic
anticoagulation is
contraindicated because
of a high risk of bleeding
or who have objectively
confirmed recurrent VTE
despite therapeutic
anticoagulation
(Consensus Level I)
Insertion of temporary IVC
filters is best restricted to
women with proven DVT
who have recurrent PE
despite adequate
anticoagulation (no
grade)
Laboratory investigations
For pregnant women
initiated on LMWH, a
baseline platelet count
should be done and
repeated a week later to
screen for HIT (III-C)
Routine measurement of
peak anti-Xa activity for
patients on LMWH for
treatment of acute VTE
in pregnancy or
postpartum is not
recommended except in
women at extremes of
body weight (less than
50 kg and 90 kg or more)
or with other
complicating factors (for
example with renal
impairment or recurrent
VTE) putting them at
high risk (C)
Routine platelet count
monitoring should not be
carried out (unless UFH
has been given) (D)
There is insufficient
evidence to recommend
monitoring of anti-Xa
levels to guide dosing in
women on therapeutic
dose LMWH (Consensus
Level I)
Suggest no routine
monitoring of LMWH
dosing with anti-Xa
LMWH (no grade)
For patients receiving
heparin in whom
clinicians consider the
risk of HIT to be\1 %,
suggest that platelet
counts not be monitored
(Grade 2C) (estimated
incidence of HIT in
obstetrics patients,
\0.1 %)25
Please see individual references for grading criteria
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Table 2C Guideline summary—prevention of first and recurrent pregnancy-associated VTE
Pre-pregnancy counselling
SOGC: Individualized risk assessment for VTE before pregnancy, once pregnancy achieved, and as new clinical situations arise; consider
patients’ values and preferences (III-B)
RCOG: Documented risk assessment for VTE in early pregnancy or pre-pregnancy; repeat if hospitalization or other intercurrent problems;
as well as intrapartum or postpartum (C)
Discuss risk of VTE and reasons for individuals recommendations with patients (no grade)
Thrombophilia testing
ACOG: Test for antiphospholipid antibodies (B) and inherited thrombophilias (C) when history of thrombosis
SOGC: No routine screening for inherited thrombophilias in women with first VTE in pregnancy (III-C)
Test for deficiencies of protein S, protein C and antithrombin following VTE in pregnancy if family history of those thrombophilias or
thrombosis at unusual site (III-C)
Test for antiphospholipid antibodies if could affect duration of anticoagulation (III-C)
RCOG: Before testing, counsel women on implications of testing for themselves and family; interpretation of results should be conducted by
clinician with specific expertise (no grade)
Test for antithrombin deficiency if family history of VTE and either antithrombin deficiency or no specific thrombophilia detected (no
grade)
Test for antiphospholipid antibodies if unprovoked VTE (no grade)
Consider thrombophilia testing even if no personal history or risk factors for VTE in the presence of history of unprovoked or estrogen-
provoked VTE in first-degree relative when aged\50 years; more informative if relative has known thrombophilia (D)
Heterozygosity for factor V leiden or prothrombin gene mutation
Antepartum
ACOG: Clinical surveillance or prophylactic LMWH or UFH (no grade)
SOGC: Clinical surveillance (no grade)
RCOG: Consider prophylaxis if C3 other risk factorsC; consider prophylaxis from 28 weeks if 2 other risk factorsC (D)
ACCP: Clinical surveillance (Grade 2C)
Postpartum
ACOG: Clinical surveillance or anticoagulation if risk factorsA (no grade)
SOGC: Clinical surveillance or 6 weeks (II-3B) prophylaxis if any C1 additional risk factors with absolute risk of VTE\1 % in isolationB
(II-2B to III-B)
ROCG: Consider prophylaxis for at least 10 days if 1 other risk factorC; consider extending to 6 weeks if family history of VTE (D)
AACP: Clinical surveillance if no family history; 6 weeks prophylaxis with prophylactic- or intermediate-dose LMWH or vitamin K
antagonists targeted at INR 2.0 to 3.0 if family history (Grade 2C)
Protein C or S deficiency
Antepartum
ACOG: Clinical surveillance or prophylactic LMWH or UFH (no grade)
SOGC: Clinical surveillance (no grade)
RCOG: Refer to local expert; consider antenatal LMWH prophylaxis (D)
ACCP: Clinical surveillance (Grade 2C)
Postpartum
ACOG: Clinical surveillance or anticoagulation if risk factorsA (no grade)
SOGC: Clinical surveillance or 6 weeks (II-3B) prophylaxis if any C1 additional risk factors with absolute risk of VTE\1 % in isolationB
(II-2B to III-B)
RCOG: 6 weeks postnatal prophylaxis (D)
ACCP: Clinical surveillance if no family history; 6 weeks postpartum prophylaxis with prophylactic- or intermediate-dose LMWH if
family history (Grade 2C)
100 S. M. Bates et al.
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Table 2C continued
Compound heterozygosity
Antepartum
ACOG: Prophylactic LMWH or UFH (no grade)
SOGC: Prophylactic LMWH (III-B)
RCOG: Refer to local expert; consider antenatal prophylaxis (D)
ACCP: Clinical surveillance (Grade 2C)
Postpartum
ACOG: Anticoagulation
SOGC: 6 weeks (II-3B) postpartum prophylactic LMWH (II-2B)
RCOG: 6 weeks postnatal prophylaxis (D)
ACCP: Clinical surveillance if no family history; 6 weeks prophylaxis with prophylactic- or intermediate-dose LMWH or vitamin K
antagonists targeted at INR 2.0–3.0 if family history (Grade 2C)
Homozygosity for factor V leiden or prothrombin gene mutation
Antepartum
ACOG: Prophylactic LMWH or UFH (no grade)
SOGC: Prophylactic LMWH (II-2A for factor V Leiden; III-B for prothrombin gene mutation)
RCOG: Refer to local expert; consider antenatal prophylaxis (D)
AACP: Clinical vigilance if no family history (Grade 2B); prophylactic or intermediate-dose LMWH if family history (Grade 2B)
Postpartum
ACOG: Anticoagulation (no grade)
SOGC: 6 weeks (II-3B) postpartum prophylactic LMWH (II-2B)
RCOG: 6 weeks postnatal prophylaxis (D)
ACCP: 6 weeks postpartum prophylaxis with prophylactic- or intermediate-dose LMWH or vitamin K antagonists targeted at INR 2.0–3.0
(Grade 2B)
Antithrombin deficiency
Antepartum
ACOG: Prophylactic LMWH or UFH (no grade)
SOGC: Prophylactic LMWH (III-B)
RCOG: Refer to local expert; consider antenatal prophylaxis (D)
ACCP: Clinical surveillance (Grade 2C)
Postpartum
ACOG: Anticoagulation
SOGC: 6 weeks (II-3B) postpartum prophylactic LMWH (II-2B)
RCOG: 6 weeks postnatal prophylaxis (D)
ACCP: Clinical surveillance if no family history; 6 weeks prophylaxis with prophylactic- or intermediate-dose LMWH or vitamin K
antagonists targeted at INR 2.0–3.0 if family history (Grade 2C)
Antiphospholipid antibody
Antepartum
ACOG: Clinical surveillance or prophylactic heparin (C)
SOGC: Intermediate or therapeutic dose LMWH (III-B)
RCOG: Consider antenatal prophylaxis throughout pregnancy if C3 other risk factorsC; consider prophylaxis from 28 weeks if 2 other risk
factorsC (D)
Postpartum
ACOG: 6 weeks postpartum anticoagulation (C)
SOGC: 6 weeks (II-3B) postpartum prophylactic LMWH (II-2B)
RCOG: 6 weeks postnatal prophylaxis (D)
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Table 2C continued
Clinical risk factors
Antepartum
SOGC: Assisted reproduction—no routine prophylaxis for ovulation induction (III-C); if severe ovarian hyperstimulation syndrome,
prophylaxis with C8–12 weeks LMWH after resolution (III-B); consider prophylaxis with LMWH if increased risk of VTE (III-B); non-
obstetrical surgery during pregnancy—prophylactic LMWH with duration dependent upon procedure and patient (III-B); strict bed rest—
prophylactic LMWH if C 7 days and BMI[25 kg/m2 at first antenatal visit (II-2B); Multiple clinical risk factors—Prophylactic LMWH
if absolute estimated VTE risk[1 %, especially if bed rest (II-2B)
RCOG: Hospitalization—offer prophylaxis with LMWH unless contraindication such as risk of labor or active bleeding (D);
Hospitalization for hyperemesis—prophylaxis with LMWH and discontinue upon resolution (C); assisted reproduction—if ovarian
hyperstimulation syndrome, prophylaxis with LMWH in first trimester (C); if IVF pregnancy and 3 other risk factorsC, prophylaxis with
LMWH in the first trimester (C); Women with C4 clinical risk factorsC should be considered for antennal LMWH throughout pregnancy;
if 3 risk factorsc, start prophylaxis at 28 weeks (D)
ACCP: Assisted reproduction—no routine thromboprophylaxis (Grade 1B); if severe ovarian hyperstimulation syndrome, 3 mo
prophylactic LMWH after resolution (Grade 2C)
Postpartum
SOGC: Strict bed rest—prophylactic LMWH if C7 days prior to delivery (II-2B); blood loss—prophylactic LMWH if[1 L peripartum or
postpartum or requiring blood product replacement and concurrent postpartum surgery (II-2B); peripartum/postpartum infection—
prophylactic LMWH (II-B); multiple clinical risk factors—6 weeks prophylaxis if risk factors ongoing or persistent (II-3B) and while
hospitalized or up to 2 weeks if transient (III-C) if any C2 risk factors with absolute risk of VTE\1 % in isolationB (II-2B to III-B) or
C3 risk factors with absolute risk of VTE of\1 %D (II-2B to III-B)
RCOG: Prophylactic LMWH dosed by weight for 10 days after delivery (D) if class 3 obesity (BMI C 40 kg/m2) (D) or C 2 risk factorsC
(B)
Prevention of recurrent VTE
Single prior episode of VTE, not receiving long-term anticoagulation
Known Thrombophilia
Heterozygosity for Factor V Leiden or Prothrombin Gene Mutation
Antepartum
ACOG: Prophylactic- or intermediate-dose LMWH or UFH or clinical surveillance (no grade)
SOGC: Prophylactic LMWH (I-A if previous event provoked, II-2A if previous event unprovoked or related to oral contraceptives or
pregnancy)
RCOG: Prophylactic LMWH throughout pregnancy (C)
ACCP: Low risk of recurrent VTE—(single episode associated with a transient risk factor not related to pregnancy or use of estrogen)
clinical vigilance (Grade 2C); moderate to high risk of recurrent VTE—(single unprovoked VTE, pregnancy-or estrogen-related VTE, or
multiple prior unprovoked VTE) not receiving long-term anticoagulation, prophylactic-or intermediate-dose LMWH (Grade 2C)
Postpartum
ACOG: Anticoagulation or intermediate dose LMWH or UFH (no grade)
SOGC: Postpartum 6 weeks (II-3B) prophylactic LMWH (II-2A)
ROCG: C6 weeks thromboprophylaxis with LMWH or warfarin (B)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH or vitamin K antagonists targeted at an INR 2.0–3.0 (Grade 2B)
Protein C or S deficiency
Antepartum
ACOG: Prophylactic- or intermediate-dose LMWH or UFH or clinical surveillance (no grade)
SOGC: Prophylactic LMWH (I-A if previous event provoked, II-2A if previous event unprovoked or related to oral contraceptives or
pregnancy)
RCOG: Prophylactic LMWH throughout pregnancy (C)
ACCP: Low risk of recurrent VTE—(single episode associated with a transient risk factor not related to pregnancy or use of estrogen)
clinical vigilance (Grade 2C); moderate to high risk of recurrent VTE—(single unprovoked VTE, pregnancy-or estrogen-related VTE, or
multiple prior unprovoked VTE) not receiving long-term anticoagulation, prophylactic-or intermediate-dose LMWH (Grade 2C)
Postpartum
ACOG: Anticoagulation or intermediate dose LMWH or UFH (no grade)
SOGC: Postpartum 6 weeks (II-3B) prophylactic LMWH (II-2A)
ROCG: C6 weeks thromboprophylaxis with LMWH or warfarin (B)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH (Grade 2B)
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Table 2C continued
Compound heterozygosity
Antepartum
ACOG: Prophylactic-, intermediate-dose or adjusted-dose LMWH or UFH (no grade)
SOGC: Intermediate- or therapeutic-dose LMWH (III-B)
RCOG: Prophylactic LMWH (D)
ACCP: Same as for heterozygosity for factor V Leiden or prothrombin gene mutation
Postpartum
ACOG: 6 weeks anticoagulation or intermediate- or adjusted-dose LMWH or UFH (no grade)
SOGC: 6 weeks (II-3B) prophylactic LMWH (II-2B)
RCOG: Prophylaxis with LMWH or warfarin for at least 6 weeks after delivery (B)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH or vitamin K antagonists targeted at an INR 2.0 to 3.0 (Grade 2B)
Antithrombin deficiency
Antepartum
ACOG: Prophylactic-, intermediate-dose or adjusted-dose LMWH or UFH (no grade)
SOGC: Intermediate- or therapeutic-dose LMWH (III-B)
RCOG: Management should be undertaken in collaboration with hematologist with expertise in thrombosis in pregnancy and
consideration given to antenatal anti-Xa monitoring and the potential for antithrombin replacement at initiation of labor or prior to
caesarean section; if anti-Xa levels measured, a test that does not use exogenous antithrombin should be used with a 4-h peak level target
of 0.5–1.0 iu/ml (no grade); higher dose LMWH (50 or 75 % of treatment dose or weight-adjusted) (D)
ACCP: Same as for heterozygosity for factor V Leiden or prothrombin gene mutation
Postpartum
ACOG: 6 weeks anticoagulation or intermediate- or adjusted-dose LMWH or UFH (no grade)
SOGC: 6 weeks (II-3B) prophylactic LMWH (II-2B)
RCOG: 6 weeks of prophylaxis with higher dose LMWH (50, 75 %, full treatment dose) or until returned to oral anticoagulant therapy (B)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH or vitamin K antagonists targeted at an INR 2.0 to 3.0 (Grade 2B)
Antiphospholipid antibody
Antepartum
ACOG: Prophylactic anticoagulation with heparin throughout pregnancy (C)
SOGC: Intermediate or therapeutic dose LMWH (III-B)
RCOG: Management should be undertaken in collaboration with a hematologist and/or rheumatologist with relevant expertise in women
with antiphospholipid antibody syndrome. These women require specialist management by an expert in thrombosis and pregnancy; higher
dose LMWH (either 50, 75 % or full treatment dose) (D)
ACCP: Same as for heterozygosity for factor V Leiden or prothrombin gene mutation
Postpartum
ACOG: 6 weeks anticoagulation with heparin (C)
SOGC: 6 weeks (II-3B) prophylactic LMWH (II-2B)
RCOG: 6 weeks thromboprophylaxis with higher dose LMWH (either 50, 75 % or full treatment dose) or until returned to oral
anticoagulant therapy (D)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH or vitamin K antagonists targeted at an INR 2.0 to 3.0 (Grade 2B)
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No known thrombophilia
Previous event associated with non-estrogen-related transient risk factor
Antepartum
ACOG: Clinical surveillance(no grade)
SOGC: Clinical surveillance (II-2A)
RCOG: If original VTE provoked by major surgery from which they have recovered and no other risk factors, thromboprophylaxis with
LMWH withheld until 28 weeks with close surveillance for the development of other risk factors; if additional risk factors, offer LMWH
(D); if original VTE related to nonsurgical transient risk factor, offer LMWH throughout the antenatal period (D)
ACCP: Low risk of recurrent VTE—(single episode associated with a transient risk factor not related to pregnancy or use of estrogen)
clinical vigilance (Grade 2C)
Postpartum
ACOG: Anticoagulation (no grade)
SOGC: 6 weeks (II-3B) prophylactic LMWH (II-2A)
RCOG: Prophylaxis with LMWH or warfarin for at least 6 weeks after delivery (B)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH or vitamin K antagonists targeted at an INR 2.0 to 3.0 (if not protein C or S
deficient) (Grade 2B)
Previous event associated with pregnancy or estrogen-related
Antepartum
ACOG: Prophylactic-dose LMWH or UFH (no grade)
SOGC: Prophylactic-dose LMWH (II-2A)
RCOG: Thromboprophylaxis with LMWH (D)
AACP: Moderate to high risk of recurrent VTE—(single unprovoked VTE, pregnancy-or estrogen-related VTE, or multiple prior
unprovoked VTE) not receiving long-term anticoagulation, prophylactic-or intermediate-dose LMWH (Grade 2C)
Postpartum
ACOG: Anticoagulation (no grade)
SOGC: 6 weeks (II-3B) prophylactic LMWH (II-2A)
RCOG: Prophylaxis with LMWH or warfarin for at least 6 weeks after delivery (B)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH or vitamin K antagonists targeted at an INR 2.0 to 3.0 (if not protein C or S
deficient) (Grade 2B)
Previous event unprovoked
Antepartum
ACOG: Prophylactic-dose LMWH or UFH (no grade)
SOGC: Prophylactic-dose LMWH (II-2A)
RCOG: Thromboprophylaxis with LMWH (D)
AACP: Moderate to high risk of recurrent VTE—(single unprovoked VTE, pregnancy-or estrogen-related VTE, or multiple prior unprovoked
VTE) not receiving long-term anticoagulation, prophylactic-or intermediate-dose LMWH (Grade 2C)
Postpartum
ACOG: Anticoagulation (no grade)
SOGC: 6 weeks (II-3B) prophylactic LMWH (II-2A)
RCOG: Prophylaxis with LMWH or warfarin for at least 6 weeks after delivery (B)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH or vitamin K antagonists targeted at an INR 2.0 to 3.0 (if not protein C or S
deficient) (Grade 2B)
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Two or more episodes, not receiving long-term anticoagulation
Antepartum
ACOG: Prophylactic- or intermediate-dose LMWH or UFH (no grade)
SOGC: As per single episode recommendations
RCOG: These patients require specialist management by an expert in thrombosis and pregnancy; higher-dose LMWH (50–75 % of
treatment dose or weight adjusted) (D)
ACCP: Moderate to high risk of recurrent VTE—(single unprovoked VTE, pregnancy-or estrogen-related VTE, or multiple prior
unprovoked VTE) not receiving long-term anticoagulation, prophylactic-or intermediate-dose LMWH (Grade 2C)
Postpartum
ACOG: 6 weeks anticoagulation or therapeutic-dose LMWH or UFH (no grade)
SOGC: As per single episode recommendations
RCOG: 6 weeks of prophylaxis with higher dose LMWH (50, 75 % or full treatment dose) (D)
ACCP: 6 weeks prophylactic-or intermediate-dose LMWH or vitamin K antagonists targeted at an INR 2.0 to 3.0 (if not protein C or S
deficient) (Grade 2B)
Two or more episodes, receiving long-term anticoagulation
Antepartum
ACOG: Therapeutic-dose LMWH or UFH (no grade)
SOGC: Therapeutic dose LMWH (III-B)
RCOG: Women should be counselled about the risks of vitamin K antagonists to the fetus and advised to stop these medications and
change to LMWH as soon as pregnancy is confirmed (ideally within 2 weeks of the missed period and before the 6th week of pregnancy)
(no grade). Thromboprophylaxis with higher dose LMWH (either 50, 75 % or full treatment dose) (D)
ACCP: If taking long-term vitamin K antagonists and candidates for LMWH substitution, suggest performing frequent pregnancy tests and
substituting LMWH for vitamin K antagonists only when pregnancy achieved (2C) [Remark: women who place little value on avoiding
the risks, inconvenience and costs of LMWH therapy of uncertain duration while awaiting pregnancy and a high value on minimizing the
risks of miscarriage associated with vitamin K antagonists are likely to choose LMWH while attempting pregnancy]. Suggest adjusted-
dose or therapeutic dose of LMWH (Grade 2C)
Postpartum
ACOG: Resumption of long-term anticoagulation (no grade)
SOGC: Resumption of long-term anticoagulation (no grade)
RCOG: Thromboprophylaxis with higher dose LMWH (either 50, 75 % or full treatment dose) for 6 weeks or until returned to oral
anticoagulant therapy after delivery (D). Warfarin can be restarted in women receiving long-term anticoagulation with this agent when the
risk of bleeding is reduced; usually 5–7 days after delivery (no grade)
ACCP: Suggest resumption of long-term anticoagulants, rather than prophylactic LMWH (Grade 2C)
Prevention of VTE associated with caesarean section
ACOG: Placement of pneumatic compression devices before caesarean delivery if not already receiving thromboprophylaxis (C)
SOGC: Following emergency caesarean section—if risk factors each with an absolute risk\1 % risk of VTE in isolation (other than
cesarean section)B, consider LMWH prophylaxis (II-2B to III-B); following elective caesarean section—if C 2 risk factors each with an
absolute risk of VTE of\1 % (other than cesarean section)D, consider LMWH (II-2B to III-B); 6 weeks postpartum prophylaxis if risk
persistent (II-3B), while risk factors ongoing, and during hospitalization; up to 2 weeks postpartum prophylaxis if risk transient (III-C)
RCOG: Emergency caesarean section—10 day thromboprophylaxis with LMWH after delivery (C); all other patients undergoing caesarean
section—consider 10 days thromboprophylaxis with LMWH after delivery if additional risk factorsE (C)
ACCP: No additional risk factors—no prophylaxis other than early mobilization (Grade 1B); 1 major risk factorF or C2 minor risk factorsG
(1 minor if emergency caesarean section)—(risk of postpartum VTE of[3 %), suggest prophylactic LMWH (if contraindication to
anticoagulation use mechanical prophylaxis (elastic stockings or intermittent pneumatic compression) while in hospital following delivery
(Grade 2B) [Remark: the reduced risk of bleeding with mechanical prophylaxis should be weighed against inconvenience of elastic
stockings and intermittent pneumatic compression]; very high risk with multiple additional risk factors persisting in puerperium—
combine prophylactic LMWH with elastic stockings and/or intermittent pneumatic compression (Grade 2C); selected high risk patients
with significant risk factors persisting after delivery—up to 6 weeks extended prophylaxis after delivery following hospital discharg
(Grade 2C)
Please see individual references for grading criteria
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Table 2D Guideline summary—anticoagulant management around the time of delivery
American College of
Obstetricians and
Gynecologists (ACOG)
[17, 18]
Society of Obstetricians
and Gynaecologists of
Canada (SOGC) [19]
Royal College of
Obstetricians and
Gynaecologists (RCOG)
[20, 21]
Australia/New Zealand
[22]
American College of
Chest Physicians (ACCP)
[23]
Antepartum: general guidance
Women receiving
prophylactic,
intermediate-dose, or
therapeutic
anticoagulation should
have a discussion about
options for analgesia/
anaesthesia prior to
delivery (III-B)
Women on LMWH for
treatment of VTE should
be advised that once she
is in established labour
or thinks she is in labour,
she should not inject any
further heparin (no
grade)
LMWH maintenance
therapy should be
discontinued 24 h prior
to planned delivery
(induction of labour or
caesarean section) (D)
Delivery options in
women using
anticoagulants are best
considered by a
multidisciplinary team.
Several options are
possible, including
spontaneous labour and
delivery, induction of
labor, and elective
caesarean section. The
plan for delivery should
take into account
obstetric, hematologic,
and anesthetic
considerations (no
grade)
Women at very high risk
for recurrent VTE (e.g.
proximal DVT or PE
close to the expected
date of delivery may
benefit by having a
planned delivery by
induction or caesarean
section as appropriate, so
that the duration of time
without anticoagulation
can be minimized (no
grade)
Antepartum: conversion to UFH
Women receiving
therapeutic or
prophylactic LMWH
may be converted to
unfractionated heparin
in the last month of
pregnancy or sooner if
delivery appears
imminent (Level C) or
planned delivery with
withholding of
anticoagulants for 24 h
(no grade)
Switching from
prophylactic LMWH to
UFH at term (37 weeks)
may be considered to
allow for more options
with respect to labour
analgesia (III-L)
Planned delivery with
conversion to
intravenous UFH in
anticipation of delivery
may be required to
minimize the time off
anticoagulants for
women at the highest
risk of recurrent VTE
(no grade)
Women at highest risk of
recurrent VTE (e.g.
proximal DVT or PE
within 2 weeks) can be
switched to intravenous
UFH prior to planned
delivery, which is then
discontinued 4–6 h prior
to the expected time of
delivery or epidural
insertion (no grade)
Antepartum: Laboratory Investigations
A recent platelet count
should be available on
admission in labour or
before caesarean
delivery in women who
have been, or are, on
anticoagulants (III-B)
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Table 2D continued
American College of
Obstetricians and
Gynecologists (ACOG)
[17, 18]
Society of Obstetricians
and Gynaecologists of
Canada (SOGC) [19]
Royal College of
Obstetricians and
Gynaecologists (RCOG)
[20, 21]
Australia/New Zealand
[22]
American College of
Chest Physicians (ACCP)
[23]
Antepartum: timing of neuraxial blockade after last dose of LMWH/UFH
It is recommended to
withhold neuroaxial
blockade for 10–12 h
after the last
prophylactic dose of
LMWH or 24 h after
the last therapeutic
dose of LMWH (Level
C)
Discontinue prophylactic
or intermediate dose
LMWH or UFH upon
the onset of spontaneous
labour or the day prior to
a planned induction of
labour or caesarean
section (II-3B)
For women on LMWH,
neuroaxial anesthesia
can be administered a
minimum of 10-12 h
after the last
prophylactic dose (III-B)
or at least 24 h after the
last therapeutic dose
(III-B)
For women on UFH,
neuroaxial anesthesia
can be administered after
no delay following a
prophylactic dose
(maximum 10,000
units/day) (III-B), at
least 4 h after stopping a
therapeutic intravenous
infusion (and when the
activated partial
thromboplastin time is
normal) (III-B), and
12 h or longer after the
last therapeutic
subcutaneous dose (and
when the activated
partial thromboplastin
time is normal) (III-B)
Neuroaxial anesthesia
must be avoided in a
women who is fully
anticoagulated or in
whom there is evidence
of altered coagulation
(II-3A)
Women taking LMWH
should be advised that
once she is in established
labour or thinks she is in
labour, she should not
inject any further heparin
(no grade)
Where delivery is planned,
LMWH therapy should
be discontinued 24 h
prior to delivery (no
grade). Regional
anesthesia or analgesic
techniques should not be
taken until at least 24 h
after the last dose of
therapeutic LMWH (no
grade) and at least 12 h
after the last dose of
prophylactic LMWH (no
grade)
For prophylactic LMWH,
a minimum of 12 h after
LMWH dose is required
prior to performance of
neuroaxial blockade (no
grade). Wait at least 2 h
following neuroaxial
blockade or catheter
removal before giving
subsequent dose (no
grade)
For therapeutic LMWH, a
minimum of 24 h after
LMWH dose is required
before performance of
neuroaxial blockade (no
grade)
For prophylactic UFH
(B10,000 units daily),
wait at least 6 h after last
dose before performing
neuroaxial blockade (no
grade). Wait at least 2 h
after performing
neuroaxial blockage or
removing neuroaxial
catheter before giving
next dose (no grade)
For therapeutic UFH, stop
intravenous UFH 4–6 h
prior to performing
neuroaxial blockade and
document a normal
activated partial
thromboplastin time
(3–4 h after stopping
infusion)(no grade).
Wait at least 1 h after
performing neuroaxial
blockage or removing
neuroaxial catheter
before restarting UFH
(no grade)
For pregnant women
receiving adjusted-dose
LMWH and where
delivery is planned,
recommend
discontinuation of
LMWH at least 24 h
prior to induction of
labour or caesarean
section (or expected time
of neuroaxial anesthesia)
rather than continuing
LMWH up until the time
of delivery (Grade 1B)
If spontaneous labour
occurs in women
receiving
anticoagulation,
neuroaxial anesthesia
should not be used.
Where the level of
anticoagulation is
uncertain and where
laboratory support
allows for rapid
assessment of heparin
levels, then testing can
be considered to guide
anesthetic and surgical
management (no grade)
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American College of
Obstetricians and
Gynecologists (ACOG)
[17, 18]
Society of Obstetricians
and Gynaecologists of
Canada (SOGC) [19]
Royal College of
Obstetricians and
Gynaecologists (RCOG)
[20, 21]
Australia/New Zealand
[22]
American College of
Chest Physicians (ACCP)
[23]
Antepartum: insertion of IVC filter
Women with DVT
within 2–4 weeks
before delivery may be
candidates for
placement of a
retrievable IVC filter
(no grade)
Consideration should be
given to the use of a
temporary IVC filter in
the perinatal period for
women with iliac vein
DVT to reduce the risk
of PE (no grade)
Women at highest risk of
recurrent VTE (e.g.
proximal DVT or PE
within 2 weeks) can
have a temporary IVC
filter inserted prior to
planned delivery and
removed postpartum (no
grade)
Postpartum: general advice—including management of women at high risk of hemorrhage
When reinstitution of
anticoagulant therapy
is planned postpartum,
pneumatic
compression devices
should be left in place
until the patient is
ambulatory and until
anticoagulation is
restarted (Level C)
In women receiving
therapeutic doses of
LMWH, wound drain
(abdominal and rectus
sheath) should be
considered at caesarean
section and the skin
incision should be closed
with staples or
interrupted sutures to
allow for drainage of any
hematoma (no grade)
Any women who is
considered to be at high
risk of hemorrhage and
in whom continued
heparin treatment is
considered essential
should be manage with
intravenous UFH until
the risk factors for
hemorrhage have
resolved (no grade)
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American College of Obstetricians
and Gynecologists (ACOG) [17, 18]
Society of Obstetricians and
Gynaecologists of Canada (SOGC)
[19]
Royal College of Obstetricians and
Gynaecologists (RCOG) [20, 21]
Australia/
New
Zealand
[22]
American
College of
Chest
Physicians
(ACCP) [23]
Postpartum: timing of resumption of anticoagulant therapy
Resumption of anticoagulation
therapy no sooner than 4–6 h
after vaginal delivery or 6–12 h
after caesarean delivery is a
reasonable approach to minimize
bleeding complications (Level B)
Removal of a neuraxial catheter left
in situ postpartum should only be
undertaken 4, 10, 12, or 24 h
following the administration of
prophylactic dose UFH (maximum
10,000 units daily), prophylactic
dose LMWH (single daily dose), or
therapeutic dose LMWH,
respectively; or in the case of
therapeutic dose UFH when the
activated partial thromboplastin
time is normal (II-3B)
Prophylactic LMWH (single daily
dose) may be started/restarted 4 h
after neuroaxial catheter removal,
provided there is full neurologic
recovery and no evidence of
activated bleeding or coagulopathy
(III-B)
Therapeutic LMWH may be started/
restarted at least 24 h after a single
injection neuroaxial block and a
minimum of 4 h after neuroaxial
catheter removal, provided there is
full neurologic recovery and no
evidence of activated bleeding or
coagulopathy (III-B)
Subcutaneous UFH may be started/
restarted at least 1 h after a single
injection neuroaxial block,
provided there is full neurologic
recovery and no evidence of
activated bleeding or coagulopathy
(III-B)
Concomitant antiplatelet agents
(acetylsalicylic acid or nonsteroidal
anti-inflammatory drugs) should
not be administered concomitantly
with heparin if a neuroaxial
catheter is left in situ postpartum
(III-D)
Women on therapeutic
anticoagulation who have received
neuroaxial anesthesia should be
monitored closely for the
development of spinal hematoma
(III-B)
The first prophylactic dose of
LMWH should be given as soon
as possible after delivery provided
there is no postpartum
hemorrhage and regional
anesthesia has not been used (no
grade)
LMWH should not be given for 4 h
after the use of spinal anesthesia
or after the epidural catheter has
been removed and the epidural
catheter should not be removed
within 12 h of the most recent
injection (D)
Women should be offered a choice
of LMMH or vitamin K
antagonists for postnatal therapy
after discussion about the need for
regular blood tests for monitoring
warfarin, particularly during the
first 10 days of treatment (no
grade)
Initiation of warfarin should be
avoided until at least the 5th day
and for longer in women at
increased risk of postpartum
hemorrhage (no grade)
Please see individual references for grading criteria
ACOG American College of Obstetricians and Gynecologists, ACCP American College of Chest Physicians, ART Assisted reproductive
technology, DVT deep vein thrombosis, HIT heparin-induced thrombocytopenia, IVF In vitro fertilization, IVC inferior vena cava, LMWH low
molecular weight heparin, RCOG Royal College of Obstetricians and Gynaecologists, SOGC Society of Obstetricians and Gynecologists of
Canada, PE pulmonary embolism, UFH unfractionated heparin, VTE venous thromboembolism
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attempted; failing that, the switch should be made as
soon as pregnancy is confirmed.
• In pregnant women with severe cutaneous allergies to
UFH or LMWH or with HIT or a history of HIT,
danaparoid or fondaparinux (if danaparoid not avail-
able) may be used. Appropriate dosage and manage-
ment of these anticoagulants around the time of
delivery should be discussed with a hematologist or
thrombosis specialist.
2. What are the risks of anticoagulation in breastfeeding
women?
Neither warfarin, the most commonly used vitamin K
antagonist in North America and the United Kingdom nor
acenocoumarol, which is commonly used in Europe, is
detected in breast milk and neither medication induces an
anticoagulant effect in the breast-fed infant when nursing
mothers consume the drug [71–74]. Phenprocoumon,
another vitamin K antagonist with a long half-life, is also
widely used outside of North America. This agent is more
lipophilic than warfarin and acenocoumarol and so can be
excreted into breast milk, although since it is highly pro-
tein-bound, the amounts detected are small [75, 76]. Small
amounts of LMWH have been detected in the breast milk
of women receiving this medication [77]; however, given
the very low bioavailability of heparin when ingested
orally [78], there is unlikely to be any clinically relevant
effect on the nursing infant. All of the guidelines that
address the issue of anticoagulant use during breastfeeding
agree that warfarin, LMWH, and UFH are safe to use in
this setting (see Table 2A) [17, 20–22]. Phencoumaron
should be reserved for women who are unstable on short-
acting acenocoumarol in countries where warfarin is not
available [76].
According to the manufacturer’s prescribing informa-
tion, fondaparinux was excreted in the milk of lactating rats
[79]. There are no published data on the excretion of
fondaparinux into human milk and the effects on the
nursing infant are unknown. The manufacturer recom-
mends that caution be used when administering fonda-
parinux to breastfeeding women [79]. That said, significant
absorption by the nursing infant would be unlikely as orally
ingested heparins have low bioavailability [78].
There are no clinical data on the effect of maternally
ingested oral direct thrombin and factor Xa inhibitors on
breastfed infants. The manufacturers of these agents all
recommend against using these medications in breast-
feeding women [35–37].
Guidance Statement
• UFH, LMWH, warfarin and acenocoumarol are safe
for the breast-fed infant when administered to the
nursing mother.
• The oral direct thrombin and factor Xa inhibitors
should not be used while breastfeeding.
3. How is venous thromboembolism during pregnancy
treated?
The guideline recommendations for management of
acute VTE during pregnancy are summarized in Table 2B.
There have been no large studies examining the safety and
efficacy of outpatient treatment of VTE diagnosed during
pregnancy. Data from the non-pregnant population suggest
that outpatient DVT treatment is not associated with an
increase in mortality, recurrent VTE, or major bleeding
[24]. In non-pregnant patients with acute DVT, outpatient
treatment is recommended as long as the patient feels well
enough to be treated at home (e.g. does not have severe leg
symptoms or comorbidity) and has well-maintained living
conditions, strong support from family or friends, tele-
phone access, and the ability to quickly return to hospital if
conditions deteriorate [24]. The safety of treating PE at
home, even in the non-pregnant population, is uncertain.
Prediction rules have been developed for identifying non-
pregnant patients with acute PE who might be suitable for
outpatient treatment because they are at low risk of serious
complications [24, 80].
The results of large trials in non-pregnant patients
demonstrating that LMWHs are at least as safe and effec-
tive as UFH for the acute treatment of VTE [81, 82] and as
vitamin K antagonists for the prevention of recurrent VTE
[83, 84], as well as data from subsequent observational
studies in pregnant women, support the use of LMWH for
treatment of VTE in this patient population [60, 61, 85, 86].
There are no large trials examining the optimal dose of
anticoagulants for treatment of acute VTE during preg-
nancy. Some pharmacokinetic studies suggest that increa-
ses in GFR and in patient weight (and, hence, LMWH
volume of distribution) that occur during pregnancy may
lead to lower LMWH levels and that the dose of LMWH
should be adjusted over the course of pregnancy to main-
tain ‘‘therapeutic’’ anti-Xa LMWH levels [87, 88], or
according to changes in weight [89]. However, other
researchers have demonstrated that few women require
dose-adjustment when therapeutic doses of LMWH are
used [90–94]. Some recommend a twice-daily LMWH
dosing schedule during pregnancy to compensate for
increases renal clearance of this medication that occur in
the second trimester. In non-pregnant patients, once daily
LMWH is as safe and effective as twice daily LMWH
when used to treat acute VTE [95]. Observational studies in
pregnant women with acute VTE have not demonstrated
any increase in the risk of recurrence with a once-daily
regimen compared with twice-daily schedules [85, 86] and
many clinicians use once-daily therapy to simplify
administration and enhance compliance.
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There are issues with reliability of anti-Xa LMWH tests
[96, 97] and these assays are costly. In the absence of
robust data demonstrating that there is an optimal ‘‘thera-
peutic anti-Xa LMWH range’’ and that dose-adjustments
increase the safety or efficacy of LMWH therapy, current
guidelines do not mandate routine monitoring of LMWH
with anti-Xa levels [21–23]. Anti-Xa monitoring may be
helpful to ensure appropriate anticoagulant effect in
patients with renal impairment and in those at the extremes
of body weight [21].
Regimens in which the intensity of LMWH is reduced
later during the course of therapy to an intermediate dose
regimen [98] or 75 % of a full treatment dose [84] have
been used successfully in cancer patients. A recent sys-
tematic review that identified four studies in which preg-
nant women with symptomatic VTE were transitioned
from full-dose anticoagulation to intermediate-dose
LMWH (less than 75 % of a full treatment dose but greater
than prophylactic dose) within 6 weeks of VTE diagnosis,
reported a low risk of VTE recurrence (one of 152 patients)
during intermediate-dose LMWH therapy; however, the
number of patients with PE was small (four) and at least
one of the included studies enrolled patients with isolated
calf vein thrombosis, which could lead to an overestimation
of the positive effect [99]. Some guidelines suggest a dose-
reduction strategy for pregnant women at risk of antico-
agulant-related bleeding and heparin-induced osteoporosis
[23] and in those with isolated calf vein thrombosis [22].
That said, a survey of members of the North American
Society of Obstetric Medicine and Thrombosis Canada
found that only one-quarter of respondents utilized this
strategy in their patients [100].
The risk of HIT in pregnant women treated with LMWH
alone is low (less than 0.1 %) [59]; it is higher in pregnant
women who have received UFH. Several guidelines sug-
gest that routine platelet count monitoring for detection of
HIT is not required in pregnant women treated exclusively
with LMWH [21, 25].
Intravenous UFH is preferred when rapid reversal of
anticoagulation may be required (i.e. in situations in
which urgent delivery or surgery may be necessary) and
in patients in whom thrombolysis may be considered (e.g.
high risk or massive PE) [24, 80]. UFH should be used in
preference to LMWH to treat acute VTE in patients with
GFR of less than 30 mL/min [80]. When UFH is pre-
ferred, it can be given intravenously or subcutaneously
every 12 h in doses adjusted to prolong a mid-interval
(6 h post-injection) activated partial thromboplastin time
(aPTT) into therapeutic range [101], although it is rec-
ognized that aPTT monitoring is less reliable in preg-
nancy [102].
Concerns about the use of thrombolytic therapy during
pregnancy center on its maternal effects (major hemor-
rhage), as well as those on the placenta (i.e. premature
labor, placental abruption, fetal demise), as transplacental
passage of tissue plasminogen activator and streptokinase
is minimal [103]. There have been several reports of suc-
cessful thrombolysis in pregnancy with no harm to the
fetus; however, the number of cases is small and most cases
involved streptokinase [104–107]. Therefore, there is
agreement amongst available guidelines that the use of
thrombolytic therapy in pregnancy is best reserved for
limb or life-threatening maternal thromboembolism (e.g.
PE with refractory cardiorespiratory compromise) [21–23,
80].
There is limited experience with inferior vena caval
filters during pregnancy and serious complications,
including filter fracture, filter migration, failed retrieval of
temporary devices, and inferior vena caval perforation,
have been reported [108–112]. Current guidelines recom-
mend insertion of temporary inferior vena caval filters in
pregnant women with acute VTE and contraindications to
anticoagulant therapy [18, 22] or recurrent VTE despite
therapeutic anticoagulation [17, 21–23]. An alternate
strategy involving anticoagulant dose-escalation may also
be appropriate for managing the latter situation, based on
favorable (but limited) data in cancer patients, in which
recurrent VTE despite anticoagulant therapy is treated by
increasing the dose of LMWH by approximately 25 % or
to therapeutic levels in those receiving lower doses [113,
114].
There are conflicting data concerning the long-term
effectiveness of graduated compression stockings to pre-
vent post-thrombotic syndrome. On the basis of two posi-
tive open label randomized trials in the non-pregnant
population [115, 116], several guidelines have suggested
that graduated compression stockings be prescribed to
reduce the likelihood of developing post-thrombotic syn-
drome [19, 22, 23]. However, a recent multicenter placebo-
controlled trial that enrolled non-pregnant patients reported
that these stockings neither prevented this complication nor
reduced the risk of recurrent VTE [117]. In addition,
although it is thought that graduated stockings may be
useful for acute symptom relief, a subgroup analysis of this
study suggests that, at least in the non-pregnant population,
this may not be the case [118].
There have been no studies assessing optimal duration
of anticoagulant therapy for treatment of pregnancy-related
VTE. In non-pregnant patients with VTE, evidence sup-
ports a minimum treatment duration of 3 months [24].
Given the increased risk of VTE in pregnant women and
following delivery, available guidelines suggest that
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anticoagulants be continued throughout pregnancy and the
postpartum period, and for a minimum of 3 months [19,
21–25].
Guidance Statement
• Outpatient treatment of VTE can be considered in
patients who are clinically stable and have good
cardiorespiratory reserve, no major risk factors for
bleeding and good social support with easy access to
medical care. Hospitalization is indicated in patients
who are hemodynamically unstable or do not have good
social support and those who have extensive VTE, or
maternal co-morbidities that limit their tolerance of
recurrent VTE or increase their risk of major bleeding.
• LMWH is the preferred anticoagulant for most preg-
nant women with acute VTE. UFH should be used
instead of LMWH in patients with GFR less than
30 mL/min. Intravenous UFH should be considered in
patients who may require thrombolysis, surgery or
urgent delivery.
• If LMWH is used for treatment of acute VTE in
pregnancy, the same weight-adjusted dosing regimen
as in the nonpregnant population should be utilized
(Table 3). Routine monitoring of LMWH dosing with
anti-Xa LMWH is likely not required.
• Thrombolytic therapy should be reserved for pregnant
women with PE associated with life-threatening car-
diorespiratory compromise or limb-threatening DVT.
• Insertion of a temporary inferior vena caval filter
should be considered in pregnant women with acute
VTE and a contraindication to anticoagulant therapy.
• Anticoagulant therapy for treatment of VTE during
pregnancy should be continued throughout pregnancy
and for at least 6 weeks postpartum for a minimum
duration of 3 months.
4. How is pregnancy-associated VTE prevented?
Decisions regarding the use of prophylactic anticoagula-
tion during pregnancy depend on the balance between the
estimated risk of VTE and associated reduction in risk with
prophylaxis, along with the burdens associated with anti-
coagulant therapy. The appropriate use of prophylaxis
depends on identifying those at sufficiently high risk of VTE
to benefit from this intervention. Risk factors to be consid-
ered include prior VTE, familial VTE history, the presence
of a known thrombophilia, and clinical factors, including
cesarean delivery, prolonged antepartum immobilization,
increased body mass index (BMI), as well as significant
pregnancy complications and medical comorbidities.
Prophylaxis during pregnancy typically involves long-
term subcutaneous injections of LMWH. Although pro-
phylactic LMWH is safe for the fetus [27, 29, 30, 49–51]
and does not appear to appreciably increase the risk of
adverse maternal outcomes [58, 59, 62–67]; it is expensive,
inconvenient and uncomfortable to administer. Depending
on local practice, prophylaxis with LMWH may also
necessitate a planned delivery to permit epidural analgesia
and women may perceive that it creates an undesirable
‘‘medicalization’’ of their pregnancy.
A Cochrane systematic review of thromboprophylaxis in
pregnancy and the early postnatal period that examined 16
randomized trials involving 2592 women concluded that
the current available information is insufficient to make
firm recommendations for prophylaxis [119]. Current
clinical guidelines are based on these small trials, addi-
tional observational studies and indirect evidence sug-
gesting that LMWH substantially decreases the risk of
VTE in a wide variety of clinical settings. As shown in
Table 2C, there is incomplete agreement between the
guidelines as to which patients should receive thrombosis
prophylaxis and only a few guidelines (SOGC [19] and
ACCP for postpartum prophylaxis [23]) explicitly provide
information about the risk threshold used to determine
whether or not patients should receive prophylaxis.
Given the competing potential drawbacks and benefits
of prophylaxis, as well as the limitations of the available
evidence, the decision to use or not use LMWH is likely to
be value and preference sensitive. In addition to holding
different attitudes toward the risk of recurrent thrombosis
and about the burdens associated with the use of prophy-
laxis, women are also likely to place varying importance on
minimizing medicalization of their pregnancy. All women,
therefore, merit an individualized risk–benefit assessment
of their need for prophylaxis and the opportunity to share in
Table 3 Accepted LMWH dosing regimens for treatment of pregnancy-related VTE
Initial
treatment
Therapeutic (adjusted-dose) LMWH
Dalteparin 200 units/kg once daily or 100 units/kg every 12 h
Tinzaparin 175 units/kg once daily
Enoxaparin 1 mg/kg every 12 h
Nadroparin 86 units/kgevery 12 h or 171 units/kg once daily
Dose
adjustments
No dose adjustment
For patients at risk for bleeding or osteoporosis and for those with isolated distal DVT, consideration can be given to
decreasing the dose to 75 % of full treatment dose after at least a month of therapy
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a decision making process about this intervention that takes
into account their values and preferences.
If the decision is made to use antepartum prophylaxis, it
should be initiated early in pregnancy as there is evidence
of an increased risk of VTE during all three trimesters
[120, 121]. Postpartum prophylaxis is less burdensome
than antepartum prophylaxis as the duration of prophylaxis
is shorter (i.e. 6 weeks) and an oral anticoagulant is
available for those uncomfortable with subcutaneous
injections (vitamin K antagonists, except for those with
protein C or S deficiency who are at risk for developing
warfarin-induced skin necrosis) [122–124].
The optimal prophylaxis strategy is unknown. Several
LMWH dosing regimens have been used for prophylaxis of
VTE during pregnancy (Table 4) [59, 62, 118, 125–133].
Although all of the studies evaluating these regimens
reported low VTE rates, most were cohort studies and,
therefore, lacked data from untreated controls. Some
investigators have reported failures of prophylactic
LMWH; however, it is unclear whether these represent true
failures or were due to noncompliance with long-term
subcutaneous injections [59, 60, 127, 134, 135]. Different
dosing strategies have not been directly compared,
although one randomized trial comparing higher doses of
LMWH prophylaxis with usual fixed dose prophylaxis is
ongoing (Highlow Randomized Controlled Trial: Com-
parison of Low and Intermediate Dose Low-molecular-
weight Heparin to Prevent Recurrent Venous Throm-
boembolism in Pregnancy; NCT001828697).
In hospitalized women, mechanical prophylaxis with
elastic stockings and/or intermittent pneumatic compres-
sion is an alternative for those with contraindications to
anticoagulant prophylaxis [23]; although there is limited
evidence that these devices are less effective at prevention
of VTE [136].
Duration of anticoagulant prophylaxis after delivery
remains controversial. Available guidelines recommend
6 weeks of postpartum prophylaxis in patients with prior
VTE and those with some thrombophilias (varies between
guidelines) [17, 19, 21, 23]. However, there is minimal
evidence to guide duration of prophylaxis in women with
other clinical risk factors and recommendations vary. A
shorter course of postpartum prophylaxis (until discharge or
for one to 2 weeks post discharge) is often suggested for
women with transient risk factors [19, 21, 23]. A recent
study that used linked primary and secondary care data to
assess VTE risk during specific postpartum periods reported
that women with pre-eclampsia/eclampsia and acute sys-
temic infection, obesity (body mass index or BMI C
30 kg/m2), and cesarean delivery had elevated VTE risks up
to 6 weeks postpartum; while VTE risk was increased only
for the first 3 weeks after delivery in those with postpartum
hemorrhage or preterm birth [137]. However, the absolute
VTE risk during those time frames was low (less than 1 %).
All pregnant women at risk of VTE should be educated
about the signs and symptoms of DVT and PE and the need
to seek urgent medical attention should they develop.
Objective testing is mandatory if symptoms suspicious of
DVT or PE occur.
Prevention of recurrent VTE
The most important individual risk factor for pregnancy-
associated VTE is a prior history of thrombosis [138]. The
absolute risk of recurrent VTE during pregnancy in women
not given antepartum prophylaxis remains controversial. In
more recent studies, the reported incidence ranged from
2.4 % (95 % CI 0.2–6.9) in a prospective study of 125
pregnant women [139] to approximately 6 % in larger
retrospective cohort studies [140, 141]. Differences in
study population (later median gestational age at enroll-
ment; inclusion of women with more than one prior epi-
sode of VTE in the retrospective studies), as well as failure
to independently adjudicate recurrent events in the retro-
spective studies, may explain the higher risk of recurrence
in the latter studies. However, the overall risk of antepar-
tum recurrent VTE in both prospective and retrospective
studies was less than 10 % and CI’s around the risk esti-
mates of individual studies are overlapping.
Data regarding prognostic factors for recurrent VTE
during pregnancy are inconsistent. Although a subgroup
analysis of the prospective cohort study mentioned above
found a lower risk of recurrence in women without
thrombophilia who had a temporary risk factor (including
oral contraceptive therapy or pregnancy) at the time of
their prior VTE, than in those with abnormal thrombophilia
testing and/or an unprovoked event [138]; in the two sub-
sequent retrospective studies, the presence or absence of a
definable thrombophilia did not appear to influence the risk
of recurrent pregnancy-associated VTE [140, 141]. Studies
in nonpregnant patients have also demonstrated that
Table 4 Suggested LMWH dosing regimens for prophylaxis against
pregnancy-related VTE
Prophylactic LMWHa
Dalteparin 5000 units once daily
Tinzaparin 4500 units once daily or 75 units/kg once daily
Enoxaparin 40 mg once daily
Nadroparin 2850 units once daily
Intermediate-dose LMWHa
Dalteparin 5000 units twice daily or 10,000 units once daily
Tinzaparin 10,000 units once daily
Enoxaparin 40 mg twice daily or 80 mg once daily
LMWH adjusted to a peak anti-Xa level of 0.2–0.6 units/mL
a Higher doses may be used in with increased maternal weight
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thrombophilic abnormalities do not play an important role
in determining the risk of recurrent VTE, despite being
clear risk factors for a first episode of DVT or PE [142].
There was a suggestion in the two retrospective studies that
women with a first VTE provoked by oral contraceptives or
related to pregnancy might be at higher risk of recurrence
in a subsequent pregnancy than those with an unprovoked
event or VTE related to a transient non-hormonal risk
factor [140, 141]. The latter findings are consistent with
those from an observational administrative dataset from
California [143].
The above data suggest that pregnant women with a
single prior episode of VTE associated with a transient risk
factor not related to pregnancy or use of estrogen are likely
at lower risk of recurrent antepartum VTE compared to
pregnant women with a history of unprovoked, pregnancy
or estrogen-related VTE. The ACCP guidelines estimated
the risk of recurrent antepartum VTE without prophylaxis
to be 2 % in the first group and 8 % in the second group
[23]. Current guidelines favor a strategy of antepartum
clinical vigilance for those with a single prior episode of
VTE associated with a transient risk factor not related to
pregnancy or hormone use and antepartum LMWH with a
history of unprovoked, pregnancy or estrogen-related VTE
[17, 19, 20, 23]. However, as the available data have sig-
nificant limitations, antepartum clinical vigilance may also
acceptable for higher risk patients accepting of the risks of
recurrence and for whom the burden of LMWH prophy-
laxis outweighs potential benefits. Similarly, women with a
prior VTE associated with a transient risk factor not related
to pregnancy or use of estrogen may benefit from
antepartum prophylaxis if they have additional major risk
factors for thrombosis. Although supportive data from
clinical trials are lacking, postpartum prophylaxis for
6 weeks with prophylactic or intermediate dose LMWH or
vitamin K antagonists targeted at INR 2.0–3.0 is generally
recommended for all pregnant women with prior VTE not
receiving long-term anticoagulants [17, 19, 20, 23].
Prevention of VTE in pregnant women with thrombophilia
and no prior VTE
Thrombophilias are laboratory abnormalities associated
with an increased risk of thrombosis and can be either
inherited or acquired. The majority of studies that have
examined the risk of VTE in pregnancy have focused on
inherited thrombophilic mutations. Although it has been
reported that approximately 50 % of pregnancy-associated
VTE are associated with inherited thrombophilia; these
abnormalities are very common and collectively are pre-
sent in at least 15 % of the population [144, 145].
As shown in Table 5, in a systematic review of nine case
control studies (n = 2526) that evaluated the association
between thrombophilia and pregnancy-associated VTE, the
highest risks were associated with homozygosity for factor
V Leiden or the prothrombin G20210A variant [146].
Pregnant women with the most common heritable throm-
bophilias (i.e. heterozygosity for factor V Leiden or the
prothrombin G20210A variant) had lower risks. Deficien-
cies of antithrombin, protein C, and protein S were associ-
ated with moderate risk increases. Estimated absolute VTE
risks, calculated using the provided odds ratios and a back-
ground incidence of VTE during pregnancy of approxi-
mately 1/1000 deliveries, suggest a low thrombosis risk
(0.5–1.2 % of affected pregnancies) for most of the inherited
thrombophilias, except perhaps for homozygous carriers of
the factor V Leiden or the prothrombin mutations, where the
risk estimate is approximately 4 % (Table 5). However,
these findings are limited by the fact that most of the
included women would not have had a family history of
VTE. A positive family history of VTE increases the risk for
VTE two- to four-fold, depending on the number of affected
relatives [147, 148] and thrombophilic subjects without a
personal or family history of DVT or PE have lower rates of
VTE than patients with thrombophilia and a positive family
history [149]. Family-based cohort studies not included in
the above-mentioned systematic review suggest that the
risks of developing a first VTE during pregnancy and the
postpartum period are two to four times greater than esti-
mated in thrombophilic women without a positive family
history (Table 5) [150–161]. However, it should be noted
that many of the events occurred during the postpartum
period and these risk estimates are very imprecise, particu-
larly for the less common thrombophilias.
Acquired thrombophilias have been less well studied but
repeated antiphospholipid antibody positivity (lupus anti-
coagulants [non-specific inhibitors], anticardiolipin anti-
bodies, or anti-b2glycoprotein-I antibodies) is associated
with an increased risk of VTE [162]. The risk or preg-
nancy-related VTE in women with antiphospholipid anti-
bodies and no previous history of venous thrombosis is
uncertain [163, 164].
There is considerable disagreement between current
guidelines about the indication for antepartum thrombosis
prophylaxis in pregnant women with deficiencies of
antithrombin, protein C, or protein S. The inconsistency in
recommendations likely results from the use of different
risk thresholds for suggesting prophylaxis, uncertainty in
risk estimates in recent studies, as described above, and
concerns about VTE risks presented in older studies that
suggested that these are high risk thrombophilias [165–
167]. However, this data is somewhat problematic as
these papers have methodologic limitations, including
acceptance of non-objectively diagnosed outcome events,
failure to clearly specify criteria for the diagnosis of VTE,
including recurrent VTE episodes in women who already
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had had a VTE, and the potential for referral and recall
bias, that have the potential to lead to an overestimation of
risk.
Prevention of pregnancy-associated VTE in patients with
clinical risk factors
Most studies that have assessed clinical and pregnancy-
related risk factors for VTE have utilized a case control or
cross-sectional design (Table 6) [3–5, 7, 87, 168–170];
although a few recent publications have used large data-
bases to provide population-level absolute and relative
risks for VTE [171, 172]. In methodologically stronger
studies, most established risk factors have only a modest
effect on VTE risk, with few increasing the absolute risk
about 1 %. How combinations of independent risk factors
might affect overall VTE risk has not been extensively
studied and in most cases, it is unclear whether
Table 5 Risks of pregnancy-related VTE in asymptomatic thrombophilic women
Thrombophilia Estimated relative risk OR (95 %CI)a Estimated absolute risk of
VTE % of pregnancies
(antepartum and postpartum) (95 % CI)
Antithrombin, protein C or protein S deficiency
Family studies 4.1 (1.6–8.3)b
3.2 (0.5–16.2) (total)c
8.3 (1.5–35.4) (no prophylaxis)c
Antithrombin deficiency
Non-family studies 4.7 (1.3–17.0) 0.7 (0.2–2.4)a
Family studies 3.0 (0.08–15.8)b
8.3 (1.4–35.4)(total)c
14.3 (2.6–51.3)(no prophylaxis)c
Protein C deficiency
Non-family studies 4.8 (2.2–10.6) 0.7 (0.3–1.5)a
Family studies 1.7 (0.4–8.9)b
0 (0–25.9) (total)c
0 (0–79.4) (no prophylaxis)c
Protein S deficiency
Non-family studies 3.2 (1.5–6.9) 0.5 (0.2–1.0)a
Family studies 6.6 (2.2–14.7)b
0 (0–32.4) (total)c
0 (0–48.9) (no prophylaxis)c
Factor V Leiden, heterozygous
Non-family studies 8.3 (5.4–12.7) 1.2 (0.8–1.8)a
Family studies 3.1 (2.1–4.6)d
Factor V Leiden, homozygous
Non-family studies 34.4 (9.9–120.1) 4.8 (1.4–16.8)a
Family studies 14.0 (6.3–25.8)e
Prothrombin G20201A, heterozygous
Non-family studies 6.8 (2.5–18.8) 1.0 (0.3–2.6)a
Family studies 2.6 (0.9–5.6)f
Prothrombin G20201A, homozygous
Non family history of studies 26.4 (1.2–559.3) 3.7 (0.2–78.3)a
a Estimated absolute risks are derived by multiplying the pooled odds ratios with their corresponding 95 % CIs from Robertson et al. [146] with
the overall baseline VTE incidence (i.e. antepartum and until 6 weeks postpartum combined) of 1.4 per 1000 [23]
b Data from Friederich et al. [160]
c Data from Mahmoodi et al. [151]
d Data from Middeldorp et al. [152], Simioni et al. [156], Middeldorp et al. [157], Simioni et al. [158], Couturaud et al. [159]
e Data from Middeldorp et al. [152], Martinelli et al. [153], Tormene et al. [153]
f Data from Bank et al. [160], and Coppens et al. [161]
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Table 6 Clinical risk factors for VTE as determined from case–control or cross-sectional studies
Risk factor Adjusted OR/
HR
95 % CI
Antepartum risk
Immobility (strict bedrest for C1 week in the antepartum period) with pre-pregnancy BMI C25 kg/m2 62.3 11.5–337.0
Immobility (strict bedrest for C1 week in the antepartum period) with pre-pregnancy BMI\25 kg/m2 7.7 3.2–19.0
Assisted reproductive techniques—first trimester 4.6 2.9–7.2
Spontaneous twins 2.6 1.1–6.2
Antepartum hemorrhage 2.3 1.8–2.8
Smoking (10–30 cigarettes/d prior to or during pregnancy) 2.1 1.3–3.4
Pre-pregnancy BMI C 25 kg/m2—no immobilization 1.8 1.3–2.4
Weight gain\7.0 kg 1.7 1.1–2.6
Postpartum risk
Immobility (strict bedrest for C1 week in the antepartum period) with pre-pregnancy BMI C25 kg/m2 40.1 8.0–201.5
Postpartum infection (clinical signs/symptoms with fever and elevated white blood cell count) following
vaginal delivery
20.2 6.4–63.5
Postpartum hemorrhage C1000 mL with surgery (curettage, evacuation of hematoma, or re-operation after
cesarean section)
12.0 3.9–36.9
Immobility (strict bedrest for C1 week in the antepartum period) with pre-pregnancy BMI\25 kg/m2 10.8 4.0–28.8
Postpartum infection (clinical signs/symptoms with fever and elevated white blood cell count) following
cesarean section
6.2 2.4–16.2
Pre-eclampsia with fetal growth restriction 5.8 2.1–16.0
Postpartum hemorrhage[1000 mL with no surgery 4.1 2.3–7.3
Fetal growth restriction (gestational age ? sex-adjusted birth weight\2.5th percentile) 3.8 1.4–10.2
Smoking (10–30 cigarettes/d prior to or during pregnancy) 3.4 2.0–4.4
Pre-eclampsia 3.1 1.8–5.3
Hyperemesis 2.5 2.0–3.2
Pre-pregnancy BMI\25 kg/m2—no immobilization 2.4 1.7–3.3
Smoking (5–9 cigarettes/d prior to or during pregnancy) 2.0 1.1–3.7
Pre-pregnancy[25 kg/m2—no immobilization 1.8 1.3–2.4
Risk period not specified
Systemic lupus erythematosus 8.7 5.8–13.0
Blood transfusion 7.6 6.2–9.4
Heart disease 7.1 6.2–8.3
Sickle cell disease 6.7 4.4–10.1
Multiple pregnancy 4.2 1.8–9.7
BMI C30 kg/m2 5.3 2.1–13.5
Assisted reproductive techniques 1.8 1.4–2.3
Anemia 2.6 2.2–2.9
Diabetes 2.0 1.4–2.7
Hypertension 1.8 1.4–2.3
Weight gain[21 kg (vs. 7–21 kg) 1.6 1.1–2.6
Parity[ 1 1.5 1.1–1.9
Data from: Lindqvist et al. [3], Simpson et al. [4], James et al. [5], Jacobsen et al. [7], Knight et al. [86], Henriksson et al. [168], Jacobsen et al.
[169]
BMI body mass index
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combinations result in additive or multiplicative risks.
Further research in this area is required.
Prevention of pregnancy-associated VTE following cesar-
ean delivery
Several observational studies have assessed the risk of VTE
after cesarean delivery. Small prospective studies in which
patients underwent screening ultrasounds following cesar-
ean section and were then followed post-discharge for at
least 6 weeks reported symptomatic VTE event rates of 0
(95 % CI 0–6.1 %) [173] and 0.5 % (95 % CI 0.1–2.8 %)
[174]. The latter is consistent with estimates based on
hospital discharge data that antedate the use of thrombosis
prophylaxis [1, 175]. Emergency cesarean delivery
approximately doubles the risk of VTE [7, 169, 172].
In the Cochrane systematic review mentioned above,
four (840 women) of the nine included trials that examined
prophylaxis following cesarean delivery compared heparin
(UFH or LMWH) with placebo [119]. There was no evi-
dence that using any form of heparin following delivery
reduced the risk of maternal VTE (risk ratio [RR] vs no
heparin for symptomatic events of 1.30; 95 % CI
0.39–4.27) and the authors concluded there was insufficient
evidence on which to base recommendations.
Guidance Statement Note: Given the uncertainty around
optimal prophylactic strategies, all women should be pro-
vided with the opportunity to participate in shared decision
making regarding this intervention, including a discussion
of VTE risks, potential benefits (reduction in VTE risk) and
drawbacks (risks of bleeding and localized skin reactions;
cost; potential limitation of analgesic options at the time of
delivery; anxiety associated with injections) of prophylaxis
along with their values and preferences. Physicians and
patients (and, perhaps, societies) with a lower threshold for
recurrent VTE may choose a more aggressive anticoagulant
strategy than recommended, whereas withholding prophy-
laxis may be appropriate in those who are willing to accept
a higher risk of recurrence in order to forgo the drawbacks
associated with prophylaxis.
General Comments
• All pregnant women at risk of VTE should be educated
about the signs and symptoms of DVT and PE and the
need to seek urgent medical attention should they
develop. Objective testing is mandatory if symptoms
suspicious of DVT or PE occur.
• All women should undergo an individualized risk
assessment for VTE prior to pregnancy, once preg-
nancy is achieved and throughout pregnancy as new
clinical situations arise.
• When considering the use of thrombosis prophylaxis
during pregnancy and/or the postpartum period, the
absolute risk of VTE, the risk reduction with prophy-
laxis, drawbacks of prophylaxis, and the woman’s
values and preferences should all be taken into
account. Given the limitations of the available data,
clinical vigilance rather than prophylaxis may also be
acceptable for patients accepting the VTE risks quoted
above and for whom the burden of LMWH prophylaxis
outweighs potential benefits.
• If the decision is made to use antepartum prophylaxis, it
should be initiated early in pregnancy.
• Six weeks of postpartum prophylaxis is recommended in
patients with prior VTE and those with some throm-
bophilias. A shorter course of postpartum prophylaxis
(until discharge or for 1–2 weeks post discharge) is
suggested for women with transient risk factors.
Prevention of recurrent VTE
• Pregnant women with prior VTE who are not receiving
long-term anticoagulation should receive 6 weeks of
postpartum prophylaxis.
• Antepartum prophylaxis should be considered in preg-
nant women with prior unprovoked VTE or pregnancy-
or estrogen-related VTE not receiving long-term
anticoagulation.
Prevention of VTE in women with thrombophilia and no
prior VTE
• Asymptomatic women who are homozygous for the
factor V Leiden mutation or prothrombin gene mutation
and who have a family history of VTE should receive
antepartum and postpartum prophylaxis.
• Consideration should be given to providing postpartum
prophylaxis in asymptomatic women who are heterozy-
gous for the factor V Leiden mutation or prothrombin
gene mutation or who have protein C or protein S
deficiency and who have a family history of VTE.
• Given the variability in the VTE risk estimates for
asymptomatic women with antithrombin deficiency and
a family history of VTE, either a strategy of antepartum
and postpartum prophylaxis or postpartum prophylaxis
alone is reasonable.
• Asymptomatic women who are homozygous for the
factor V Leiden mutation or prothrombin gene mutation
and who have no family history of VTE should receive
postpartum prophylaxis.
• Asymptomatic women with all other thrombophilias
who do not have a family history of VTE do not require
prophylaxis, in the absence of other risk factors.
However, given the variability in the VTE risk estimates
for asymptomatic women with antithrombin deficiency
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and no family history of VTE, consideration could also
be given to utilizing postpartum prophylaxis in these
patients.
Prevention of VTE in women with clinical risk factors
• Antepartum prophylaxis should be provided to immo-
bilized (strict bedrest) women with a pre-pregnancy
BMI of at least 25 kg/m2 and to those with a prior
history of VTE regardless of their BMI. Consideration
should be given to providing prophylaxis during
antepartum immobilization (as defined above) to
women with a lower body mass index who have other
significant comorbidities (e.g. systemic lupus erythe-
matosus, sickle cell disease, heart disease) associated
with an increased risk of VTE or a thrombophilia.
• Consideration should be given to providing postpartum
prophylaxis while in hospital to women with a history
of antepartum immobilization (as defined above) for at
least 7 days and to those who are immobilized
postpartum who have a known thrombophilia or
significant medical comorbidity
Prevention of VTE in after cesarean delivery
• Prophylaxis should be provided after cesarean delivery
to women with the following risk factors:
One or more of prior VTE, a history of antepartum
immobilization (strict bedrest for at least 1 week),
significant postpartum infection, postpartum hemor-
rhage of at least 1000 mL requiring re-operation,
pre-eclampsia with growth restriction, significant
medical co-morbidities (systemic lupus erythemato-
sis, heart disease, or sickle cell disease) or a known
thrombophilia.
Two or more of (or one or more in the setting of
emergency cesarean delivery) of postpartum hemor-
rhage of at least 1000 mL that does not require re-
operation, BMI[30 kg/m2, fetal growth restriction,
pre-eclampsia, multiple pregnancy and tobacco use
during pregnancy (at least 10 cigarettes per day)
5. How is peripartum anticoagulation managed?
The delivery options in women using anticoagulants are
best considered by a multidisciplinary team in order to min-
imize the risks of maternal hemorrhage, epidural hematoma,
and VTE around the time of delivery. In a systematic review
of 2777 pregnancies in which LMWH was utilized in either
therapeutic or prophylactic doses, postpartum hemorrhage of
greater than 500 mL occurred in 26 pregnancies (0.94 %;
95 % CI 0.61–1.37 %) and wound hematoma in 17 preg-
nancies (0.61 %, 95 % CI 0.36–0.98 %) [59]. A more recent
systematic review of 18 studies that focused solely on preg-
nant women (n = 981) receiving treatment for acute VTE
during pregnancy reported an incidence of major bleeding
during the first 24 h after delivery of 1.90 % (95 % CI
0.80–3.60 %) [60]. Although epidural hematomas in obstet-
rical patients receiving epidural analgesia/anesthesia are rare,
with an estimated incidence of less than 1 in 150,000 [176];
the potential complications are devastating and include per-
manent neurologic dysfunction.
Depending on local practice, delivery options include
spontaneous labor and delivery, induction of labor, and
planned cesarean delivery. Induction of labor may help to
avoid an unwanted anticoagulant effect during delivery
(especially with neuroaxial anesthesia) in women receiving
LMWH. Current guideline recommendations for manage-
ment of anticoagulant therapy around the time of delivery
are outlined in Table 2D. Anesthesia and obstetrical
guidelines agree that 24 h should pass between the last
dose of therapeutic LMWH and insertion of a neuroaxial
catheter [17, 19–23, 177]. For prophylactic LMWH,
catheter insertion should occur no sooner than 10–12 h
after the last LMWH dose [17, 19–23, 177].
At some centers, women are converted from therapeutic
adjusted-dose LMWH to subcutaneous twice daily thera-
peutic dose UFH in the last month of pregnancy. However,
therapeutic doses of subcutaneous UFH may cause a per-
sistent anticoagulant effect. One study reported that six of
11 women receiving subcutaneous UFH during pregnancy
had an elevated aPTT at delivery despite discontinuing
their injections at the onset of labour to 12 h prior to
elective induction [178].
Patients should be instructed to withhold their injections
if they believe that they have entered labor spontaneously.
In centers with laboratory support that allows for rapid
assessment of heparin levels, testing can be considered to
guide anesthetic and surgical management; otherwise time
since last injection should be used. If anticoagulation pre-
cludes regional techniques, alternative analgesic options
include intravenous analgesia or general anesthesia for
cesarean delivery [20–22].
The potential increased risk of wound hematoma after
cesarean delivery in patients receiving anticoagulant ther-
apy has led to the suggestion that wound drains and closure
techniques that allow easy hematoma drainage be consid-
ered in this population [179]. If bleeding occurs that is
considered secondary to LMWH rather than an obstetric
cause, protamine sulfate may provide partial neutralization
[180].
Women diagnosed with proximal DVT or PE within
two to 4 weeks of delivery are at very high risk for
recurrent VTE with prolonged anticoagulant cessation
[181, 182]. A strategy involving planned delivery with
transition to intravenous UFH will minimize time off
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Table 7 Summary of guidance statements
Question Guidance statement
1. What are the risks of
anticoagulant use during
pregnancy?
Physicians should counsel women receiving long-term therapy with vitamin K
antagonists and the oral direct-acting anticoagulants about the fetal risks of these
medications before pregnancy occurs
LMWH is the drug of choice for treatment and prevention of VTE in pregnancy,
except in patients with HIT, a history of HIT, or significant renal dysfunction.
UFH is preferred in patients with significant renal dysfunction
For women taking vitamin K antagonists, two options are available to reduce the
risk of warfarin embryopathy. The first is to advise women to perform frequent
pregnancy tests and substitute LMWH for warfarin once pregnancy is achieved
and before 6 weeks gestation. Alternatively, LMWH or UFH can be substituted
for vitamin K antagonists before conception is attempted
Although the latter approach minimizes the risks of early miscarriage associated
with vitamin K antagonist therapy, it lengthens the duration of exposure to LMWH
or UFH and, therefore, is costly and exposes the patient to a greater burden of
treatment associated with the use of injectable heparin therapy. Since warfarin
embryopathy is unlikely to result from warfarin exposure before 6 weeks, the first
option is usually favored by guidelines. Although the management of women who
are receiving long-term therapy with oral direct thrombin and factor Xa inhibitors
and attempting to conceive remains controversial, it has been suggested that these
women should be converted to a coumarin or LMWH before conception is
attempted; failing that, the switch should be made as soon as pregnancy is
confirmed
In pregnant women with severe cutaneous allergies to UFH or LMWH or with HIT
or a history of HIT, danaparoid or fondaparinux (if danaparoid not available) may
be used. Appropriate dosage and management of these anticoagulants around the
time of delivery should be discussed with a hematologist or thrombosis specialist
2. What are the risks of
anticoagulation in
breastfeeding women?
UFH, LMWH, warfarin and acenocoumarol are safe for the breast-fed infant when
administered to the nursing mother
The oral direct thrombin and factor Xa inhibitors should not be used while
breastfeeding
3. How is venous
thromboembolism during
pregnancy treated?
Outpatient treatment of VTE can be considered in patients who are clinically
stable and have good cardiorespiratory reserve, no major risk factors for bleeding
and good social support with easy access to medical care. Hospitalization is
indicated in patients who are hemodynamically unstable or do not have good
social support and those who have extensive VTE, or maternal co-morbidities that
limit their tolerance of recurrent VTE or increase their risk of major bleeding
LMWH is the preferred anticoagulant for most pregnant women with acute VTE.
UFH should be used instead of LMWH in patients with GFR less than 30 mL/min.
Intravenous UFH should be considered in patients who may require thrombolysis,
surgery or urgent delivery
If LMWH is used for treatment of acute VTE in pregnancy, the same weight-
adjusted dosing regimen as in the nonpregnant population should be utilized
(Table 3). Routine monitoring of LMWH dosing with anti-Xa LMWH is likely not
required
Thrombolytic therapy should be reserved for pregnant women with PE associated
with life-threatening cardiorespiratory compromise or limb-threatening DVT
Insertion of a temporary inferior vena caval filter should be considered in pregnant
women with acute VTE and a contraindication to anticoagulant therapy
Anticoagulant therapy for treatment of VTE during pregnancy should be continued
throughout pregnancy and for at least six weeks postpartum for a minimum
duration of three months
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Table 7 continued
Question Guidance statement
4. How is pregnancy-
associated VTE
prevented?
General comments
All pregnant women at risk of VTE should be educated about the signs and
symptoms of DVT and PE and the need to seek urgent medical attention should
they develop. Objective testing is mandatory if symptoms suspicious of DVT or
PE occur
All women should undergo an individualized risk assessment for VTE prior to
pregnancy, once pregnancy is achieved and throughout pregnancy as new clinical
situations arise
When considering the use of thrombosis prophylaxis during pregnancy and/or the
postpartum period, the absolute risk of VTE, the risk reduction with prophylaxis,
drawbacks of prophylaxis, and the woman’s values and preferences should all be
taken into account. Given the limitations of the available data, clinical vigilance
rather than prophylaxis may also be acceptable for patients accepting the VTE
risks quoted above and for whom the burden of LMWH prophylaxis outweighs
potential benefits
If the decision is made to use antepartum prophylaxis, it should be initiated early in
pregnancy
Six weeks of postpartum prophylaxis is recommended in patients with prior VTE
and those with some thrombophilias. A shorter course of postpartum prophylaxis
(until discharge or for one to 2 weeks post discharge) is suggested for women with
transient risk factors
Prevention of Recurrent VTE
Pregnant women with prior VTE who are not receiving long-term anticoagulation
should receive 6 weeks of postpartum prophylaxis
Antepartum prophylaxis should be considered in pregnant women with prior
unprovoked VTE or pregnancy- or estrogen-related VTE not receiving long-term
anticoagulation
Prevention of VTE in Women with Thrombophilia and no Prior VTE
Asymptomatic women who are homozygous for the factor V Leiden mutation or
prothrombin gene mutation and who have a family history of VTE should receive
antepartum and postpartum prophylaxis
Consideration should be given to providing postpartum prophylaxis in
asymptomatic women who are heterozygous for the factor V Leiden mutation or
prothrombin gene mutation or who have protein C or protein S deficiency and who
have a family history of VTE
Given the variability in the VTE risk estimates for asymptomatic women with
antithrombin deficiency and a family history of VTE, either a strategy of
antepartum and postpartum prophylaxis or postpartum prophylaxis alone is
reasonable
Asymptomatic women who are homozygous for the factor V Leiden mutation or
prothrombin gene mutation and who have no family history of VTE should receive
postpartum prophylaxis
Asymptomatic women with all other thrombophilias who do not have a family
history of VTE do not require prophylaxis, in the absence of other risk factors.
However, given the variability in the VTE risk estimates for asymptomatic women
with antithrombin deficiency and no family history of VTE, consideration could
also be given to utilizing postpartum prophylaxis in these patients
Prevention of VTE in women with clinical risk factors
Antepartum prophylaxis should be provided to immobilized (strict bedrest) women
with a pre-pregnancy BMI of at least 25 kg/m2 and to those with a prior history of
VTE regardless of their BMI. Consideration should be given to providing
prophylaxis during antepartum immobilization (as defined above) to women with a
lower body mass index who have other significant comorbidities (e.g. systemic
lupus erythematosus, sickle cell disease, heart disease) associated with an
increased risk of VTE or a thrombophilia
Consideration should be given to providing postpartum prophylaxis while in
hospital to women with a history of antepartum immobilization (as defined above)
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therapeutic anticoagulation [22, 23]. Discontinuation of
intravenous UFH four to 6 h prior to the expected time of
delivery or epidural insertion with a repeat activated
partial thromboplastin time drawn after 4 h to confirm
normalization will ensure that there is no residual anti-
coagulant effect. For the highest risk patients (e.g. VTE
within 2 weeks), consideration can be given to insertion
of a temporary inferior vena caval filter that can be
removed postpartum.
Anticoagulants should be recommenced post-delivery as
soon as adequate hemostasis is assured. Guidelines gener-
ally recommend resumption of prophylactic LMWH four
to 12 h following delivery [17, 19]; and not sooner than 4 h
after epidural catheter removal (with a longer delay for
bloody or traumatic neuroaxial procedures) [177]. There
are no definitive recommendations for resumption of full-
dose LMWH following epidural catheter removal; how-
ever, it appears safe to do so 24 h of catheter removal
(again, with a delay if placement was bloody or traumatic)
[19, 22]. The timing of resumption of postpartum vitamin
K antagonists for patients who choose this option remains
controversial; some guidelines recommend a delay of at
least 5 days [21, 22], although this recommendation
appears based on the results of a single centre retrospective
audit [183]. Once an INR of at least 2.0 is achieved,
bridging LMWH can be discontinued.
Table 7 continued
Question Guidance statement
for at least 7 days and to those who are immobilized postpartum who have a
known thrombophilia or significant medical comorbidity
Prevention of VTE in after Cesarean Delivery
Prophylaxis should be provided after cesarean delivery to women with the following
risk factors:
One or more of prior VTE, a history of antepartum immobilization (strict bedrest
for at least 1 week), significant postpartum infection, postpartum hemorrhage of at
least 1000 mL requiring re-operation, pre-eclampsia with growth restriction,
significant medical co-morbidities (systemic lupus erythematosis, heart disease, or
sickle cell disease) or a known thrombophilia
Two or more of (or one or more in the setting of emergency cesarean delivery) of
postpartum hemorrhage of at least 1000 mL that does not require re-operation,
BMI[30 kg/m2, fetal growth restriction, pre-eclampsia, multiple pregnancy and
tobacco use during pregnancy (at least 10 cigarettes per day)
5. How is peripartum
anticoagulation managed?
All pregnant women receiving anticoagulants should have an individualized
delivery plan that addresses obstetrical, anesthetic and thrombotic concerns
All pregnant women should be advised to discontinue anticoagulant therapy upon
the onset of spontaneous labor
If there is a planned delivery, therapeutic LMWH should be discontinued at least
24 h prior to the expected time of epidural analgesia or delivery. Prophylactic
LMWH should be stopped at least 10–12 h prior to epidural analgesia
For planned deliveries, intravenously administered unfractionated heparin should be
stopped at 4–6 h prior to the expected time of epidural analgesia or delivery and
the aPTT checked to ensure normalization. For therapeutic doses of unfractionated
heparin administered subcutaneously, the last dose should be given no sooner than
12 h and preferably closer to 24 h prior to expected time of epidural analgesia or
delivery and the aPTT checked to ensure normalization. Guidelines differ in their
requirement for a delay prior to epidural analgesia in patients receiving
prophylactic dose unfractionated heparin up to 10,000 units daily; when possible
prophylactic unfractionated heparin should be discontinued 8–10 h prior to
planned procedures
Prophylactic LMWH may be started/restarted 6–12 h after delivery (no sooner than
4 h after epidural catheter removal), as long as hemostasis is assured and there has
not been a bloody or traumatic epidural. For prophylactic unfractionated heparin,
the recommended time interval from epidural catheter removal is one to 8 h
Therapeutic LMWH may be started/restarted 24 h after delivery (no sooner than
24 h after epidural catheter removal), as long as hemostasis is assured and there
has not been a bloody or traumatic epidural. Attainment of therapeutic levels of
intravenous unfractionated heparin should be delayed for the same amount of time
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Guidance Statement
• All pregnant women receiving anticoagulants should
have an individualized delivery plan that addresses
obstetrical, anesthetic and thrombotic concerns.
• All pregnant women should be advised to discontinue
anticoagulant therapy upon the onset of spontaneous
labor.
• If there is a planned delivery, therapeutic LMWH
should be discontinued at least 24 h prior to the
expected time of epidural analgesia or delivery.
Prophylactic LMWH should be stopped at least
10–12 h prior to epidural analgesia.
• For planned deliveries, intravenously administered
unfractionated heparin should be stopped at 4–6 h prior
to the expected time of epidural analgesia or delivery
and the aPTT checked to ensure normalization. For
therapeutic doses of unfractionated heparin adminis-
tered subcutaneously, the last dose should be given no
sooner than 12 h and preferably closer to 24 h prior to
expected time of epidural analgesia or delivery and the
aPTT checked to ensure normalization. Guidelines differ
in their requirement for a delay prior to epidural
analgesia in patients receiving prophylactic dose unfrac-
tionated heparin up to 10,000 units daily; when possible
prophylactic unfractionated heparin should be discon-
tinued 8–10 h prior to planned procedures.
• Prophylactic LMWH may be started/restarted 6–12 h
after delivery (no sooner than 4 h after epidural catheter
removal), as long as hemostasis is assured and there has
not been a bloody or traumatic epidural. For prophy-
lactic unfractionated heparin, the recommended time
interval from epidural catheter removal is one to 8 h.
• Therapeutic LMWH may be started/restarted 24 h after
delivery (no sooner than 24 h after epidural catheter
removal), as long as hemostasis is assured and there has
not been a bloody or traumatic epidural. Attainment of
therapeutic levels of intravenous unfractionated heparin
should be delayed for the same amount of time.
Conclusion
Women are at increased risk of VTE during pregnancy
and the postpartum period. Treatment and prevention of
VTE in this patient population is complicated by the
need to consider fetal, as well as maternal, wellbeing
when making management decisions. Although our
knowledge of risk factors for pregnancy-related VTE and
the safe and effective use of anticoagulants used to
prevent and treat VTE in this population continues to
increase, there are still important gaps and high quality
research in this area should be a priority. In the interim,
all women should be provided with the opportunity to
participate in shared decision making regarding their
management. To make the best decisions, absolute risks
and potential benefits of interventions, guideline recom-
mendations, and patient values and preferences should all
be taken into account. Table 7 summarizes these guid-
ance statements.
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